Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
_______________________________________________________________ _________________________________________ 
 Pragmatic Return to Effective Dental Infection 
Control through Triage and Testing 
(PREDICT) 
PBRN Feasibility Study 
NIDCR Protocol Number: 20-067-E    
NIDCR Grant Number:  X01 DE030407 – 01  
Principal Investigator:  Cecile A. Feldman, DMD, MBA  
Grantee Institution:  Rutgers University, Sch ool of Dental Medicine  
NIDCR Program Official:  Dena Fischer, DDS, MSD, MS  
NIDCR Medical Monitor:  N/A 
Draft or Version Number:  Vr. 4.0  
August 15, 2021  
 
STATEMENT OF COMPLIANCE 
The study will be conducted in a ccordance with the Internationa l Council for Harmonisation guidelines for 
Good Clinical Practice (GCP) (I CH E6) and the Code of Federal R egulations on the Protection of Human 
Subjects (45 CFR Part 46). Nati onal Institutes of Health (NIH)- funded investigators and clinical trial site 
staff who are responsible for  the conduct, management, or overs ight of NIH-funded clinical trials have 
completed Human Subjects Prote ction and ICH GCP Training. 
  
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 2  Revision History: 
Version 
Number  Date  Summary of Revisions Made: 
1.01  7/25/21  Added revision history table; doubled enrollment t o account for not all 
consented individuals will go on to complete the protocol; adde d Abbot 
BinaxNOW Covid‐19 Ag Card and COVID‐19 Antigen SelfTEST as POC  tests; 
added collection of tongue cells  for PCR testing; removed dupli cate patient 
consent; added activiti es occurring with de signated window as o utcome 
measures; removed patient triage  the night prior to visit; spec ified event 
performed outside of a window is  not considered a protocol devi ation; clarified 
nasal, tongue cell and capillary  blood specimen collection to s elf‐collection for 
the PBRN member and by the PBRN  practitioner or his/her designe e for other 
DHCWs and the patient subjects;  changed UPS package drop‐off to  be at UPS 
store or drop box rather than th e dental office; removed eligib ility requirement 
that a DHCW have a smart phone;  added eligibility requirement t hat patient 
subjects have access to a compute r or electronic tablet with in ternet 
connection and that they be comput er literate enough to be able  to complete 
the consent and survey questionnaires; updated event reporting  table 
    
    
    
 
 
  
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 3  SIGNATURE PAGE 
The signatures below constitut es the approval of this protocol and the attachments, and provides the 
necessary assurances that this s tudy will be conducted accordin g to all stipulations of the protocol, 
including all statements regard ing confidentiality, and accordi ng to local legal and regulatory requirements 
and applicable US federal regulations and ICH guidelines. 
Principal Investigator: 
Signed:   Date:   
Name:  Cecile A. Feldman, DMD 
Title:    Dean and Professor, Rutge rs University, School of Den tal Medicine 
 
Co-PI: 
Signed:   Date:   
Name:  Daniel Fine, DMD 
Title:    Chair and Professor, Rutge rs University, School of De ntal Medicine 
  
 
  
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 4  TABLE OF CONTENTS 
PAGE 
STATEMENT OF COMPLIANCE  .............................................................. .................................1  
SIGNATURE PAGE  .............................................................. ........................................................2  
TABLE OF CONTENTS  .............................................................. .................................................3  
LIST OF ABBREVIATIONS  .............................................................. ...........................................5  
PROTOCOL SUMMARY ............................................................... ...............................................8  
1 KEY ROLES AND CONT ACT INFORMATION  .............................................................1 0 
2 INTRODUCTION: BACKGROUND IN FORMATION AND SCIENTIFIC 
RATIONALE  .............................................................. ..........................................................13  
2.1 Background Information  .............................................................. ..........................13  
2.2 Rationale  .............................................................. ....................................................13  
2.2.1 Potential Risks  .............................................................. ..............................14  
2.2.2 Potential Benefits  .............................................................. .........................14  
3 OBJECTIVES AND OUTCOME MEASURES  .............................................................. .15 
3.1 Primary  .............................................................. .......................................................17  
3.2 Secondary  .............................................................. .................................................18  
3.3 Tertiary/Exploratory  .............................................................. ..................................20  
4 STUDY DESIGN ............................................................... ..................................................19  
5 STUDY POPULATION  .............................................................. ........................................20  
5.1 Participant Inclusion Criteria  .............................................................. ...................20  
5.2 Participant Exclusion Criteria  .............................................................. .................20  
5.3 Strategies for Recruitment and Retention  ..........................................................20  
5.4 Participant Withdrawal or Di scontinuation from Study 
Procedures/Intervention  .............................................................. ..........................21  
5.4.1 Reasons for Participant Withdrawal  or Discontinuation from Stud y 
Procedures/Intervention  .............................................................. ..............21  
5.4.2 Handling of Participant Withdrawal s from Study or Participant 
Discontinuation of Study Intervention  .....................................................22  
5.5 Premature Termination or Suspension of Study  ...............................................22  
6 STUDY SCHEDULE  .............................................................. ............................................25  
6.1 Dental Health Care Worker Subjects  .............................................................. ....25 
6.2 Patient Subjects  .............................................................. ........................................25  
6.3 Unscheduled Visit  .............................................................. ....................................26  
7 STUDY PROCEDURES/EVALUATIONS ............................................................... ........27 
7.1 Study Procedures/Evaluations  .............................................................. ...............34 
7.2 Lab Procedures/Evaluations  .............................................................. ..................37 
7.2.1 Clinical Laborat ory Evaluations  .............................................................. ..40 
7.2.2 Specimen Preparation , Handling,and Storage  ......................................41  
7.2.3 Specimen Shipment  .............................................................. .....................41  
9 ASSESSMENT OF SAFETY  .............................................................. ..............................41  
8.1 Specification of Safety Parameters  .............................................................. .......41 
8.1.1 Unanticipated Problems  .............................................................. ..............41  
8.1.2 Serious Adverse Events  .............................................................. ..............42  
8.2 Reporting Procedures  .............................................................. ..............................42  
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 5  8.2.1 Unanticipated Problem Reporting  ............................................................42  
9 STUDY OVERSIGHT  .............................................................. ..........................................44  
10 CLINICAL SITE MONITORING  .............................................................. .........................44  
11 STATISTICAL CONSIDERATIONS  .............................................................. ..................46  
11.1 Final Analysis Plan  .............................................................. ...................................45  
12 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ........46 
13 QUALITY CONTROL AND QUALITY ASSURANCE  ...................................................47  
14 ETHICS/PROTECTION OF HUMAN SUBJECTS  ........................................................50  
14.1 Ethical Standard  .............................................................. .......................................50  
14.2 Institutional Review Board  .............................................................. ......................50  
14.3 Informed Consent Process  .............................................................. .....................50  
14.4 Exclusion of Women, Minorities, and Children (Special Populatio ns) ...........50  
14.5 Subject Confidentiality  .............................................................. .............................50  
14.6 Future Use of Stored Specim ens and Other Identifiable Data  ........................51  
15 DATA HANDLING AND RECORD KEEPING  .............................................................. .52 
15.1 Data Management Responsibilities  .............................................................. .......52 
15.2 Data Capture Methods  .............................................................. ............................52 
15.3 Types of Data  .............................................................. ............................................53 
15.4 Schedule and Content of Reports  .............................................................. .........53 
15.5 Study Records Retention  .............................................................. ........................53  
15.6 Protocol Deviations  .............................................................. ..................................53  
16 PUBLICATION/DATA SHARING  .............................................................. .......................54  
17 LITERATURE REFERENCES  .............................................................. ...........................56  
APPENDIX MATERIALS ............................................................... .............................................58  
 
  
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 6  LIST OF ABBREVIATIONS 
AE Adverse Event/Adverse Experience 
PBRN Practice Based Research Network CFR Code of Federal Regulations CSI Clinical Site Investigator CIOMS Council for International Organizations of Medical Scienc es 
CONSORT Consolidated Standards of Reporting Trials CRF Case Report Form CRO Contract Research Organization DCC Data Coordinating Center DHCW Dental Health Care Workers DHHS Department of Health and Human Services DMFS Decayed, missing, and  filled tooth surfaces 
DSMB Data and Safety Monitoring Board eCRF Electronic Case Report Form FDA Food and Drug Administration FFR Federal Financial Report FWA Federalwide Assurance GCP Good Clinical Practice HIPAA Health Insurance Portab ility and Accountability Act 
ICF Informed Consent Form ICH International Coun cil for Harmonisation 
ICMJE International Committee
 of Medical Journal Editors 
IRB Institutional Review Board ISM Independent Safety Monitor LAB Laboratory Based Saliva-Based COVID-19 Test MOP Manual of Procedures N Number (typically ref ers to participants) 
NIDCR National Institute of Dent al and Craniofacial Research, N IH, DHHS 
NIH National Institutes of Health OCTOM Office of Clinical Trials Operations and  Management, NIDC R, NIH 
OHRP Office for Human Re search Protections 
PHI Protected Health Information PI Principal Investigator 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 7  PO Program Official, NIDCR, NIH 
POC Point-of-Care COVID-19 Test 
PREDICT  
Pragmatic Return to Effective D ental Infection Control through Triage and 
Testing 
PS Project Scienti st, NIDCR, NIH 
QA Quality Assurance QC Quality Control QoL Quality of Life SAE Serious Adverse Event/Serious Adverse Experience SOP Standard Operating Procedure UP Unanticipated Problem US United States WHO World Health Organization 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 8  PROTOCOL SUMMARY 
Title: Pragmatic Return to Effective D ental Infection Control through Triage and 
Testing: PBRN Feasibly Study 
Précis: We will conduct a feasibility st udy to develop and assess proce dures for 
improved COVID-19 triage and te sting in dental practices to inc rease safety 
and perceptions of safety of Dental  Health Care Workers (DHCWs)  and 
their patients. Four National Dent al Practice-Based Research Ne twork 
(PBRN) member dentists and thei r office staff will be recruited  to participate 
as either as a Point of Care (POC ) Office or a LAB office based  upon 
preference of the PBRN member dentist. . In the POC offices, we  will test 
out procedures for POC/SARS-CoV- 2 antigen testing in DHCWs and 
patients of the practice along wi th enhanced triage using pulse  oximeters.  
In the LAB offices, DHCWs and pat ients will test procedures for  a saliva-
based laboratory SARS-CoV-2 viral test (LAB) along with enhance d triage 
methods.  Based on office recruit ment (POC or LAB), viral, anti gen and/or 
antibody COVID-19 tests will be adm inistered to DCHW and patien ts 
entering the dental office. In addition, the use of pulse oxime ters will be 
added to the DHCW and patient tr iage protocol.  The feasibility  of 
implementing COVID-related test ing and enhanced triage procedur es in the 
dental setting will provide prelim inary data to inform a larger  network-wide 
study grant application.    
   
Objectives: Primary:   The primary objective of this st udy is to assess the feasibil ity of 
procedures for both COVID-19 point -of-care and lab-based testin g along 
with enhanced triage in dental offices.   
 
Population: This study will take place in  dental offices, each of which wi th at least one 
National Dental PBRN member d entist.  DHCWs working in a dental  office 
with a participating National  Dental PBRN dentist and their adu lt patients 18 
years old and older will be rec ruited to participate.  In each office, up to 10 
DHCWs (dentists, hygienists, a ssistants and office staff) inclu ding  the 
PBRN member dentists and up to tw enty (20) patients will be enr olled.  In 
total, up to forty (40) DHCW (dentists, hygienists, assistants and office staff 
will be enrolled) and eighty (80) patients enrolled.   
Number of Sites: Four (4) National Dental PBRN offices 
Study Duration: Twelve (12) months 
Subject Participation 
Duration: DHCWs in both POC offices and L AB offices will participate in t he study for 
1 month.  Patients being seen in P OC or LAB offices will partic ipate in the 
study for approximately two (2) weeks.   
Estimated Time to 
Complete Enrollment: Six (6) months 
 
  
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Pr otocol Template v5.0–20190311  Page 9  Schematic of Study Design  
  
 
 
  
 
 

Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 10  1.0 KEY ROLES AND CO NTACT INFORMATION  
 
Principal Investigator:   Cecile A. Feldman, DMD, MBA  
 Dean and Professor 
 Rutgers University, School of Dental Medicine  110 Bergen Street 
 Newark, NJ 07103 
 Phone:  (973) 972-4634 
 Fax:  (973) 972-3689 
 feldman@rutgers.edu  
NIDCR Program Officer:  Dena Fischer, DDS, MSD, MS 
 National Institute of Dental  & Craniofacial Research 
 6701 Democracy Boulevard, MSC 4878 
 Bethesda, MD  20892-4878 
 Phone: (301) 594-4876  Dena.fischer@nih.gov 
 
Grants Management Specialist:  Mr. Gabe Hidalgo 
 National Institute of Dental  & Craniofacial Research 
 6701 Democracy Boulevard, MSC 4878 
 Bethesda, MD  20892-4878  Phone:  (301) 827-4630 
 gabriel.hidalgo@nih.gov 
 
Other Key Personnel: 
 
Chief Oral Biologist (and Co-PI):  
 Daniel Fine, DMD 
 Rutgers University, Sch ool of Dental Medicine 
 110 Bergen Street 
 Newark, NJ 07103 
 Phone:  (973) 972-7056  Fax:  (973) 972-0045 
 finedh@sdm.rutgers.edu 
 
  Chief Clinical Protocol Off icer and Co-Investigator:  
 Janine Fredericks-Younger, DMD 
 Rutgers University, School of Dental Medicine  110 Bergen Street, Room D813 
 Newark, NJ   07101 
 Phone:  (973) 972-1679  Fax:  (973) 972-5040 
 frederja@sdm.rutgers.edu 
 
Chief Epidemiologist and Co-Investigator :    
 Modupe Coker 
 Rutgers University, School of Dental Medicine 
 110 Bergen Street, Room B815  
 Newark, NJ 07101  Phone:  (973) 762-4430 
 Fax:  (908) 477-0056 
 mc2190@sdm.rutgers.edu 
 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 11  Chief Biostatistician and Co-Investigator:  
 Amy Davidow, PhD  Rutgers University, School of Public Health 
 683 Hoes Lane  Piscataway, NJ  08854 
 Phone:  (732) 235-5764 
 Fax:  (732) 235-5464 
 davidoal@sph.rutgers.edu  
  
Co-Investigator :    
 Gayathri Subramanian 
 Rutgers University, School of Dental Medicine  110 Bergen Street, Room B815  
 Newark, NJ 07101 
 Phone:  (973) 762-4430  Fax:  (908) 477-0056 
 subramga@sdm.rutgers.edu  
 
 Co-Investigator :    
 Maria Gennaro 
 Rutgers University, New Jersey Medical School  NJMS-PHRI Center 
 225 Warren Street  
 Newark, NJ 07101  Phone:  (973) 854-3210 
 marila.gennaro@rutgers.edu 
 
Program Manager: 
 Julie Chapman-Greene 
 Rutgers University, School of Dental Medicine 
 110 Bergen Street, Room B824 
 Newark, NJ 01701  Phone: (973) 972-3620 
 chapmaje@sdm.rutgers.edu 
 
PBRN Regional Node Direct or (Northeast Region): 
 Cyril Meyerowitz, DDS, MS 
 University of Rochester, Eastm an Institute for Oral Health  
265 Crittenden Blvd, Box 686, Saunders Research Bldg 
Rochester, NY 14642 
Phone: (585) 275-4935 cyril_meyerowitz@urmc.rochester.edu 
 
PBRN Regional Node  Coordinator (Northeast Region): 
 Pat Ragusa 
University of Rochester, Eastm an Institute for Oral Health 
625 Elmwood Avenue Box 683 Rochester, NY 14620 
Phone (585) 275-5780 
 Pat_Ragusa@URMC.Rochester.edu  
 
PBRN Director of t he Specialty Node: 
 Veerasathpurush Allareddy BDS PhD  Department of Orthodontics, College of Dentistry 
University of Illinois at Chicago 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 12  801 S. Paulina St., 138AD (MC841) 
Chicago, IL 60612-7211 
Phone: (312) 996-1809 
sath@uic.edu 
 
Network Coordinating Center (NCC) Study Manager: 
Sara Gille, MPH Kaiser Permanente Northwest 
Center for Health Research 3800 N Interstate Avenue 
Portland, OR 97227 
Phone:  (971) 232-0939 Sara.Gille@kpchr.org  
 
Network Coordinating Center (NCC) Director: 
MaryAnn McBurnie Kaiser Permanente Northwest 
Center for Health Research 3800 N Interstate Avenue 
Portland, OR 97227 
Phone:  (503) 335-2400 
maryann.mcburnie@kpchr.org  
 
Network Coordinating Center (NCC) Statistician: 
Ellen Funkhouser, Dr Ph 
Medical Towers 611 
1717 11th Avenue South 
Birmingham, Alabama 35205 
Phone: (205) 934-1120 
Fax: (205) 934-7959 
emfunk@uab.edu  
 
Administrative and Resource Center (ARC) Director: 
Gregg Gilbert, DDS, MBA University of Alabama at Bir mingham School of Dentistry 
SDB Room 109 
Birmingham, Alabama 35205  
Phone: 205-934-5423 
ghg@uab.edu  
 
Administrative and Resource Ce nter (ARC) Project Manager: 
Andi Mathews Hand, RDH 
University of Alabama at Bir mingham School of Dentistry 
SDB Room 109 
Birmingham, Alabama 35205  
Phone: 205-934-2578 
ahmathews@uab.edu 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 13  2 INTRODUCTION: BACKGROUND INFORM ATION AND SCIENTIFIC RATIONALE   
2.1 Background Information 
 
Description of Problem:    
 
        The COVID-19 pandemic: COVID-19 has created serious concerns about the safety of patients and 
dental professionals as they return to a practice environment. The spread of this ubiquitous virus was first 
thought to be through droplets but soon it became clear that th e virus could be spread by aerosols [5,6]. 
Many dental procedures require the mechanical preparation of ha rd and soft tissue using high speed 
handpieces which are water cooled and generate significant aero solized sprays. The extent to which 
dentally-generated aerosols linger within operatories has not b een clearly tested but it is certain that clinic 
dental personnel will be exposed to significant aerosol sprays derived from patients’ oral cavities [7]. As we 
learn more about COVID-19 and vi ral transmission we understand that infection and spread of the virus is 
due to the viral load (or dose) and the time of contact [8,9].  
 
Uniqueness of Dental Practice:   Unlike many procedures in medi cine, dental/patient contact is  eye 
to eye with close proximity bet ween patient and dental professi onals [10]. Furthermore, a dental procedure 
can often take as long as 1 hour and prolonged close contact be tween dentist and patient is inevitable. 
Despite personal protective equi pment (PPE) that includes N95 m asks, face shields, gowns, and high-
speed suction, viral spread from infected patients is likely in  the dental setting. This suggests that the only 
safe solution for maintaining the health and safety of dental p rofessionals in the time of COVID-19 is 
removing virus-infected pati ents from their offices [11].  
 
    Waiting Rooms and Airflow:  Obvious issues confronting dent al practices have been discusse d, 
however, waiting rooms with pati ents, bathrooms and passageways  are all additional areas within offices 
that can be of safety concern. Further, the airflow in confined  office spaces where patients can be waiting 
for 30 minutes or more can be hazardous if an asymptomatic but COVID-19 infected patient is in close 
proximity to a susceptible patient. Patients in a dental office  can be at risk for infection that can have varied 
presentation and severity and may be life threatening especiall y in patients with pre-existing conditions [21-
23].    
    Solutions:  One way of providing the security that dental offices are safe  for both the dental professional 
and patient is by taking measures  to prevent anyone who harbors  the COVID-19 virus from entering the 
office. This of course would necessitate testing every patient at every visit or by est ablishing the fact that 
patients are safe if they have neutralizing antibody to the COV ID-19 virus. These solutions, at this moment, 
appear to be impractical particularly if the virus affects a ve ry small percentage of the population, testing is 
inaccurate, and obtaining testing results is not immediate. A s olution to this problem is imperative both for 
the safety and security of the patient and dental professional.  But what’s to be done? How do we achieve 
our goal of providing a safe and secure environment that allows  for routine dental care?  
 
Several challenges exist to routine and comprehensive testing: The costs, turnaround time (maximum 
practical utility would perhaps be derived from a simple, rapid , accurate, inexpensive point-of-care test that 
is not technically demanding, and such a test has not yet been validated). This proposal compares the use 
of one such candidate POC test wit h the current screening gold- standard. 
 
     Conclusions : With each day, patients are not receiving dental services beca use of a COVID-19 
transmission concern. Understandi ng risk associated with COVID- 19 transmission in a dental practice and 
the effective use of testing and other practice modifications c ould dramatically reduce the risk, facilitating 
dental health care providers and pat ients to be comfortable wit h seeking/providing essential dental services.  
This proposal is designed to develop procedures that address th is serious problem and test the feasibility 
of these procedures in a pragmatic  manner to address this exist ing insurmountable problem that can affect 
the future of dental practice and  the dental health we have com e to expect. 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 14   
2.2 Rationale 
 
    Typical dental protocols reco mmend twice yearly visits to d entists for prevention and maintenance of oral 
health [12,13]. Dental patients who may be asymptomatic for med ical conditions are seen routinely in dental 
offices and can be screened for the early phases of medical dis ease during routine dental visits. For 
example, blood pressure monitoring and simple blood test for gl ycosylated hemoglobin (HbA1c) levels can 
be performed in dental offices, with referral to medical person nel for further assessment [18,19]. This 
medical screening can be considered as value-added should denta l health professionals provide 
augmented diagnostic benefit to pat ients who are unaware of the ir need for medical intervention. However, 
in this time of uncertainty dentistry has been impacted by fear  and poorly defined strategies to mitigate 
COVID-19, that can compromise the willingness of dental profess ionals to open their dental practices [20]. 
     Little is Known Regarding the Effectiveness COVID-19 Triage  in Dental Practice :  Little is known 
about the effectiveness of triage protocols which have been rec ommended by the CDC.  For example, most 
offices are using temporal thermometers, yet many are uncalibra ted.  In addition, screening questions 
continue to evolve, and the vera city of patient responses remai ns unverified.  
     Little is Known Regarding the Impact of COVID-19 Testing in  Dental Practice:   Little is known about 
the value of testing and about the willingness of dental health  care workers (DHCW) to implement COVID-
19 testing in a dental office, who would pay for the testing, o r the most effective use of such testing. 
 
The following questions need to be answered: 
 Perception of safety and comf ort: Will patients and DHCW in an  office with either LAB or POC 
testing feel safer and be more co mfortable delivering/receiving  care during a COVID-19 or other 
infectious disease pandemic?   
 Testing preference: Do DHCW and patients prefer POC testing ra ther than testing that requires 
laboratory processing?  
 Effectiveness of triage: Is the tr iage protocol being followed  today effective or do patients and 
DHCW respond negatively to COVID -19 symptoms because of the fea r of not being seen or 
being turned away from work? 
 Effectiveness of triage methods: A re objective measures such a s temperature and pulse oximeter 
readings effective in identifying “asymptomatic” cases? 
2.2.1 Potential Risks 
This research involves testing procedures with varying degrees of risk to the study participants.  
 Saliva Test- minimal risk.  The saliva test is non-invasive, r equires spitting into a tube, and is 
completed independently, without interaction with a member of t he healthcare team. 
 Nasal swab- minimal risk. The nasal swab involves insertion of  a swab into the forward part of the 
nasal cavity (not beyond the nar es) by a member of the healthca re team which may cause slight 
discomfort to the participant.   
 Tongue swab – minimal risk.  T he tongue swab involves rolling a small circular brush on the 
tongue to collect epithelial cell s which may cause slight disco mfort to the participant. 
 Finger prick- minimal risk. A  finger prick test is a procedure  in which a finger is pricked with a 
lancet to obtain a small quantit y of capillary blood for testin g. The site where the blood is to be 
collected is sterilized with a t opical germicide, and the skin is pierced with a sterile lancet.  There 
is a slight risk of discomfort  from the lancet stick and irrita tion or infection in the area the where 
the lancet punctures the skin. 
 
In addition, different COVID-19  test types have varying degrees  of sensitivity and specificity, which may 
result in false negative and fals e positive test results. A fal se negative result may give a participant a false 
sense of security, and the pat ient would have been treated with  each office’s infection control protocol 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 15  regardless of participation in  the study.  Regardless, false ne gative test results may pose additional viral 
transmission risk to DHCW who interact with and treat the patie nt, and other individuals who come into 
contact with the asymptomatic but infected patient. On the othe r hand, a false positi ve result will prompt 
the DHCW or patient to undergo additional testing by their prim ary health care provider and may cause 
additional anxiety.  Should they  test positive again, they woul d need to follow their local health 
department recommendations which may require quarantine.   
 
There is a risk of loss of con fidentiality for all study partic ipants. Precautions will be in place to minimize 
this risk, such as collecting only minimal identifying informat ion, using unique study codes for participants, 
collecting data using encrypted computers, and maintaining elec tronic data files on a password-protected 
computer drive, and storing data on encrypted computers or in l ocked cabinets (located in locked offices). 
Individual identifier numbers that are linked to participant co ntact information will be stored separately 
from the data. Compliance with all IRB regulations concerning d ata collection, data analysis, data 
storage, and data destruction will be strictly observed. 
2.2.2 Potential Benefits 
There is no benefit to DHCW and pa tients participating in this study beyond the fact that DHCW and 
patients would receive the resu lts of the COVID-19 tests they u ndergo.   
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 16  3 OBJECTIVES AND OUTCOME MEASURES 
3.0 Feasibility Study Outcomes 
Objectives   Brief Description/Justification of 
Outcome Measure Outcome Measured By   Time Frame 
To Determine DHCW and 
Patient Willingness to 
Participate Willingness to participate is 
important in determining whether 
dental offices, DHCW and patients 
would be willing to participate in a large‐scale study 
  Ratio of DHCW agreeing to participate as 
compared to all DHCW asked to 
participate 
 
 Ratio of patients agreeing to participate 
as compared to all patients asked to 
participate 
 
 Thoroughness of consent process and 
ability to ask questions  Willingness to Participate:  
 DHCW – at time of consent by 
DHCW consent 
 Patients – at ti me of consent 
by patients  
To Determine DHCW and 
Patient  Willingness/Ability to  
Follow Thru with Triage, 
Testing and Survey 
Administration Procedures 
 
 Determining willingness and ability to 
follow thru with triage, testing and 
survey administration procedures is 
important for refining the survey 
procedures For both DHCW and Patients 
 
 % who complete the study 
 
 % who complete surveys 
o Start‐of‐Study DHCW Survey 
o End‐Of‐Study DHCW Survey 
o Pre‐Visit Patient Survey 
o End‐of‐Visit Patient Survey 
 
 % activities occurring  within the defined 
window 
o Consents 
o Start‐of‐Study DHCW Survey, Triage 
and Testing 
o End‐Of‐Study DHCW Survey, Triage 
and Testing 
o Mid‐Study Triage Testing 
o Pre‐Visit Patient Survey 
o End‐of‐Visit Patient Survey 
o Patient Testing 
 
 % who feel testing (Saliva, PCR, POC, and 
ELISA Antibody) procedure was easy to 
comply with 
o Specimen collection 
o Specimen preparation for shipping 
o Specimen storage 
o Timeliness of results 
o Reporting of results 
 
 % Complete Study:  
 For DHCW ‐ At time End‐of‐
Study (Day 28) 
 Patients – End‐Of‐Visit (Day 1) 
 % All Surveys Completed:  
 For DHCW ‐ At time End‐of‐
Study (Day 28) 
 Patients – End‐Of‐Visit (Day 1) 
 
% Activities Occurring within the 
defined window:  
 For DHCW – Consent, Start‐of‐
Study Visit, Mid‐Visit, End‐of‐
Study Visit 
 Patients – Consent, LAB 
material receip t, LAB specimen 
sent to laboratory, LAB results, 
Treatment Visit 
 % Feel Testing Protocol was Easy 
to Comply With:  
 For DHCW ‐ At time End‐of‐
Study (Day 28) 
 Patients – End‐Of‐Visit (Day 1) 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 17  Objectives   Brief Description/Justification of 
Outcome Measure Outcome Measured By   Time Frame 
To Determine Ease of Use with 
REDCap Survey Instruments 
 Dental Health Care Worker 
Subject 
o Start‐of‐Study Survey 
o End‐of‐Study Survey 
o Triage Survey 
 Patient Subject 
o Start‐of‐Visit Survey 
o End‐of‐Visit Survey 
o Triage Survey 
 Determining the  ease of use and 
completeness of the REDCap 
instruments enables refinement of 
the system For both DHCW and Patients 
 
 % who feel surveys are easy to complete 
due to administration method: 
o Start‐of‐Study DHCW Survey 
o End‐of‐Study DHCW Survey 
o Pre‐Visit Patient Survey 
o End‐of‐Visit Patient Survey 
o Triage Case Report 
 
 % who feel survey questions were 
understandable: 
o Start‐of‐Study DHCW Survey 
o End‐of‐Study DHCW Survey 
o Pre‐Visit Patient Survey 
o End‐of‐Visit Patient Survey 
o Triage Case Report 
 
 % completed surveys: 
o Start‐of‐Study DHCW Survey 
o End‐of‐Study DHCW Survey 
o Pre‐Visit Patient Survey 
o End‐of‐Visit Patient Survey 
o Triage Case Report  
 
% indicating surveys were easy to 
complete due to administration method: 
 For DHCW ‐ At time End‐of‐
Study (Day 28) 
 Patients – End‐Of‐Visit (Day 1) 
 % indicating survey questions were easy to understand:  
 For DHCW ‐ At time End‐of‐
Study (Day 28) 
 Patients – End‐Of‐Visit (Day 1) 
 
% Surveys Completed:  
 For DHCW ‐ At time End‐of‐
Study (Day 28) 
 Patients – End‐Of‐Visit (Day 1) 
 
 
    
3.1 Primary Outcomes for Full Stu dy (Data Collection is Being P erformed to 
Determine Instrument Feasibility)    
Full Study Objective  Brief Description/Justification of 
Outcome Measure Outcome Measured By   Time Frame 
Objective 1 – Dental health 
care personnel feel safe in the 
dental office   
 Safety Culture Evaluation Survey  for 
DHCW is a 6‐item survey using a 4 
point Likert scale seeking the 
agreement with 6 cri teria associated 
high performing safety organization 
characteristics. 
 
Willingness to Come to Work  reflects 
a DHCW’s safety in  the workplace. 
 
Willingness to Refer Other Patients  
reflects DHCW’s safety of the dental 
practice. DHCW ‐ Safety Culture Evaluation Survey:   6 
item survey.  Numeric responses to each 
item using a four‐point Likert Scale are 
summed for a score which reflects the level 
of safety in the organization.  (1=strongly 
agree, 2=agree, 3=dis agree, 4=strongly 
disagree.) 
 DHCW‐ Safety:   How safe to do feel coming 
to work? 5 Point Likert scale 
 
DHCW Willingness to Refer Other Patients:   
How likely would you refer a family or friend to this dental office?  5 Point Likert Scale 
 Sense of Safety for Dental Health 
Personnel: 
 Start of study 
 End of study 
 
Willingness to Refer Other 
Patients:  
 DHCW – Start of study 
 DHCW – End of study 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 18  3.2 Secondary Outcomes for Full Study (Data Collection is Being  Performed to 
Determine Instrument Feasibility) 
Objective  Brief Description/ Justification of 
Outcome Measure Outcome Measured By   Time Frame 
Objective 2:   Determine the 
Efficiency and Effectiveness 
of: 
 Efficiency of DHCW Triage 
Protocols 
 Efficiency of Patient 
Triage Protocols 
 Effectiveness Patient 
Testing Protocols 
 
 
  
 
 Efficiency of Tri age Protocols:   
 Acceptability of triage protocols 
is based upon resources (time and effort and facilities) 
required to implement the 
protocol   
Effectiveness of Triage Protocols 
 Dentist’s willingness to continue 
use of triage protocols is based upon the usefulness/outcomes of 
the triage.   
 
Efficiency of Testing Protocols:   
 Acceptability of testing protocols 
is based upon resources (time and effort and facilities) required to implement the 
protocol  
 
Effectiveness of Testing Protocols 
 Dentist’s willingness to implement 
testing protocols is likely to be based upon testing’s ability to 
identify asymptomatic DHCW and 
patients. 
 
 Efficiency of Tri age Protocols:   
 Time needed to complete triage survey 
 Effectiveness of Triage Protocols 
 Comparison of number of DHCW not able to 
report to work due to LAB or POC test results 
 Comparison of Triage Survey to Medical 
History consistent with COVID‐19 symptoms 
for DHCW 
 
Efficiency of Testing Protocols:   
 Time and supplies needed to conduct LAB vs. 
POC test 
 Effectiveness of Testing Protocols 
 Comparison of number of DHCW not able to 
report to work  
 Comparison of number of patients not able 
to report for thei r patient visits  Efficiency of Tri age Protocols:   
 End of study 
 Effectiveness of Triage Protocols 
 End of study 
 
Efficiency of Testing Protocols:   
 End‐of‐Study 
 Effectiveness of Testing Protocols 
 End‐of‐Study 
 
 
3.3 Tertiary/Exploratory Outcomes  for Full Study (Data Collecti on is Being 
Performed to Determine Instrument Feasibility)  
Objective  Brief Description/Justification of 
Outcome Measure Outcome Measured By   Time Frame 
Objective 3 (exploratory):  
Examine SARS‐CoV‐2 Positivity 
Rate and Immuno‐Conversion 
Rate 
 DHCW positivity rate   
 DHCWs with IgG  
 DHCWs with IgM  
 DHCWs who immune‐convert    
 Positivity Rate:    
 POC antigen with  a nasal swab 
 PCR with a saliva or tongue 
scraping specimen 
Immuno‐conversion Rate 
 ELISA with Capillary Blood 
specimen DHCW Positivity Rate:    
 POC antigen 
 PCR viral test 
 
DHCW Immuno‐conversion Rate 
 ELISA antibody DHCW Positivity Rate:    
 Start of Study 
 Every 2 weeks 
 End of Study 
 
DHCW Immuno‐conversion Rate 
 Start‐of‐Study 
 Every 2 Weeks 
 End‐of‐Study 
 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 19  4 STUDY DESIGN 
Description:   This observational study will assess the feasibility of imple menting COVID-related testing 
and triage procedures in the dental  setting to ensure the safet y of DHCWs and patient s. Results from this 
study may provide preliminary dat a to inform a larger network-w ide study grant application. 
 This study will be conducted in  four (4) private practice denta l offices, each of which with at least one 
National Dental Practice Based Research Network (PBRN) member d entist. Based upon preference of 
the Practice Based Research Net work dentist, offices will parti cipate as either a Point of Care (POC) 
Office (2 offices) or a LAB o ffice (2 offices). In the POC offi ces, we will test procedures for POC/SARS-
CoV-2 antigen testing in DHCWs and patients of the practice alo ng with enhanced triage using pulse 
oximeters.  In the LAB offices, D HCWs and patients will test pr ocedures for a saliva-based laboratory 
SARS-CoV-2 viral tes t (LAB) along with enhanced triage methods.  The National Dental PBRN dentist and 
office will choose to participat e in either the POC or LAB grou p; offices will not be assigned to study 
groups.  
 
Study Population: The study population for this s tudy will be all dentists, hygie nists, dental assistants 
and dental office personnel (e. g., dentists, hygienists, dental  assistants, front office  staff) working in a 
participating dental office, as w ell as patients being treated in the participating dental office.   
 Important Outcomes:   For this study, important outco mes include percent of both DH CW and patients 
willing to participate percent com pleting the protocol. See Sec tion 3 for more detail. 
 
Number of Study Groups: Four (4) 
1. DHCW in POC Offices 
2. Patients in POC Offices 3. DHCW in Lab Offices 
4. Patients in Lab Offices 
 
Expected Duration of Sub ject Participation:   
 DHCWs (in POC or LAB Offices) - 1 month 
 Patients (in POC or L AB Offices) - 2 weeks 
 
Sequence of Procedures and Duration of Study Period:  See Section 7. 
 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 20  5 STUDY POPULATION 
5.1 Participant Inclusion Criteria 
A Dental Health Care Worker  must meet all of the following cr iteria to be eligible to part icipate in the 
study: 
 Be 18 years or older  
 Be a National Dental PBRN member  dentist or work in a dental o ffice with a National Dental 
PBRN member dentist who conse nts to study participation 
 Be able to understand the informed consent. 
 Provide signed and dated i nformed consent form 
 Be able to understand all instru ctions for data collection ins truments  
 Be willing and able to comply wi th all study procedures, inclu ding COVID-19 testing, and be 
available for the dur ation of the study  
 
A Patient  must meet all of the following cri teria to be eligible to part icipate in the study: 
 Be 18 years or older 
 Be able to understand the informed consent. 
 Have a computer or electronic  tablet with internet access 
 Able to complete consent and que stionnaire on a computer or el ectronic tablet 
 Provide signed and dated i nformed consent form 
 Be able to understand all instru ctions for data collection ins truments  
 Be willing and able to comply wi th all study procedures, inclu ding having a COVID-19 test 
performed 
 
5.2 Participant Exclusion Criteria 
Participants would be excluded if they participated in the feas ibility study previously  conducted  at Rutgers 
University. 
5.3 Strategies for Recr uitment and Retention 
Target Sample Size:  40 dental care health workers and 80 patients. 
Target Sample Size by Gender, Race, Ethnicity, and Age:   Study population will be drawn from 
National Dental PBRN dentist mem bers, their co-workers and pati ents seen in their office.  Any adult 18 
years and older meeting the in clusion criteria and not meeting any exclusion criteria will be eligible to 
participate.  It is expected tha t the mix of gender, race and e thnicity will reflect the patient mix of the 
participating dental offices. 
 
Study Population:  The DHCW study population will be dentists, hygienists, assista nts and office staff 
who work in an office with a National Dental PBRN member dentis t.  The patient study population will be 
drawn from the dental practice with the National Dental PBRN me mber dentist.   
 Inclusion of Women and Minoriti es and Individuals of All Ages:  
Women:   Women will be includ ed in this study.   
Minorities:  Minorities will be included in this study.   
 
Recruitment Strategies:   Four (4) National Dental PBRN practitioners who have 4 or mor e DHCW in 
their office will be recruited to  participate by the National D ental PBRN Node Coordinator.  The Node 
Coordinator will then recruit DHC Ws within the practice to part icipate.  If a practice is unable to consent at 
least 5 DHCWs, the practice will not participate in the study.  Another National Dental  PBRN practice will 
be recruited to participate.   
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 21  Patients will be sent a letter about 4 weeks prior introducing the study by the PBRN practitioner.  The 
PBRN practitioner or PBRN invest igators in the office will reac h out to patients by phone about 2 weeks 
prior to the dental visit.  The study will be explained and if the patient is interested , an e-mail link will be 
sent which will allow the patien t to review the informed consen t.  A phone number will be provided to 
answer questions. 
 
Recruitment Protoco l (All Study Groups):  
 The PRBN Node Research Coordinat or will recruit PBRN dentist me mbers to participate  in the protocol.  
The PBRN Node Research Coordinat or will contact PBRN dentist me mbers to introduce the study and 
gauge initial interest.  The dent al office will be enlisted if the PBRN dentist member and 4-9 additional 
office DHCWs of the practice are  willing to participate and the  PBRN member is willing to perform the 
responsibilities of t he protocol including enrolling and comple ting 10 patients. The PBRN practitioner’s 
preference will determine which  protocol (POC or LAB) will be f ollowed in the office. In total, two POC 
offices will participate, and tw o LAB offices will participate.  
 
Office  Study Group Protocol COVID-19 Related Tests (Method)
POC 1- DHCW in POC Offices 
 POC DHCW Protocol  Antigen (nasal swab) 
 Antibody (capillary blood) 
2- Patients in POC Offices POC Patient Protocol  Antigen (nasal swab) 
LAB 3- DHCW in Lab Offices LAB DHCW Protocol  Virus (saliva and/or tongue) 
 Antibody (capillary blood) 
4- Patients in LAB Offices LAB Patien t Protocol  Virus (saliva) 
 
 Retention:  In order to minimize loss of st udy participants and/or incomple te data collection, the following 
activities will take place: 
 Node Coordinators w ill work with National  Dental PBRN study pa rticipants responsible for 
recruiting subjects and comple ting surveys to encourage patient  enrollment and study completion. 
 Participants will rece ive compensation.   
 
Compensation and Scheduled Payments:   DHCWs who complete the st udy procedures including the 
end-of-study survey will receive $125 each.  Patients who compl ete the LAB study procedures including 
the post-visit survey will be pr ovided $100 and patients who co mplete the POC study procedures 
including the post-visit s urvey will be provided $50.   
 
Additional Plans to Minimize  Missing or Incomplete Data:  The following will minimize missing or 
incomplete data: 
 When appropriate, REDCap survey  data fields are set to “requir ed”.   
 REDCap validation rules on data fields to limit responses to t hose which are valid  
5.4 Participant Withdrawal or Di scontinuation from Study Proced ures/ 
Intervention 
5.4.1 Reasons for Participant Withdr awal or Discontinuation from Study 
Procedures/ Intervention 
Participants are free to withdra w from participation in the stu dy at any time upon request. 
 An investigator may discontinue an individual’s participation i n an intervention or withdraw an individual 
from the study if: 
 The participant has a serious adverse event requiring hospital ization. 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 22   Any clinical adverse event ( AE), laboratory abnormality, or ot her medical condition or situation 
occurs such that continued par ticipation in the study would not  be in the best interest of the 
participant. 
 The participant meets an exclusi on criterion (either newly dev eloped or not previously 
recognized) that precludes further study participation.  
5.4.2 Handling of Participant Withdrawals from Study  
Participants may withdraw parti cipation consent at any time, ei ther verbally or in writing. Participants who 
further withdraw their consent for  the use of data already coll ected must do so in writing. The Node 
Coordinator will interview t he participant and document the wit hdrawal of consent using the Consent 
Withdrawn Received Form in the REDCap system.  Documentation in cludes the date, the reason for 
participant withdrawal, as well as the upload of any written wi thdrawal request. Upon wi thdrawal, all study 
procedures would cease, however, the participant would be offer ed continued care as part of the normal 
standard of care. 
 
Participants who withdr aw will not be replaced. 
5.5 Premature Termination or Suspension of Study 
This study may be su spended or prematurely terminated if there is sufficient reasonable cause.  Written 
notification, documenting the re ason for study suspension or te rmination, will be provided by the 
suspending or terminating party to Dr. Cecile Feldman and the f unding agency (NIDCR). The principal 
investigator will also promptly inform the sIRB and NIDCR and w ill provide the re ason(s) for the 
termination or suspension.  
 
Circumstances that m ay warrant terminati on include, but are not  limited to: 
 Determination of unexpected, s ignificant, or unacceptable risk  to participants. 
 Insufficient adherence to protocol requirements.   
 Data that are not sufficientl y complete and/or evaluable.  
 Determination of futility. 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 23  6 STUDY SCHEDULE 
6.1 Dental Health Care Worker Subjects  
The following is the schedule of e vents for Dental Health Care Worker Subjects in the POC Offices.   
 
Visit  
Day Dental Health Care Worker Subjects 
Activities Performed 
Enrollment 
(15 minutes) Day ‐28  
(+/‐ 29 days)  Obtain written Informed Consent 
Start‐of‐Study 
(35 minutes) Day 0  
  Complete Start‐of‐Study Survey 
 Complete Start‐of‐Study  Triage Case Report 
 Undergo POC (antigen) COVID‐19 test  
 Provide specimen for ELISA (antibody) test 
Mid‐Study 
(20 minutes) Day 14   
(+/‐ 7 days)  Complete Mid‐Study Triage Case Report 
 Undergo POC Covid‐19 Test 
End‐of‐Study 
(40 minutes) Day 28 
(+/‐ 14 days)  Complete End‐of‐Study  Triage Case Report 
 Undergo POC COVID‐19 Test  
 Provide specimen for ELISA (antibody) test 
 Complete End‐of‐Study Survey 
 Complete DHCW Particip ation Questionnaire 
The following is the schedule of e vents for Dental Health Care Worker Subjects in the LAB Offices.   
 
Visit  
Day Dental Health Care Worker Subjects 
Activities Performed 
Enrollment  
(15 minutes) Day ‐28  
(+/‐ 29 days)  Obtain written Informed Consent 
Start‐of‐Study  
(35 minutes) Day 0  
  Complete Start‐of‐Study Survey 
 Complete Start‐of‐Study  Triage Case Report 
 Provide specimen(s) for PCR (viral) test 
 Provide specimen for ELISA (antibody) test 
Mid‐Study  
(20 minutes) Day 14   
(+/‐ 7 days)  Complete Mid‐Study Triage Case Report 
 Undergo POC Covid‐19 Test 
End‐of‐Study  
(40 minutes) Day 28 
(+/‐14 days)  Complete End‐of‐Study  Triage Case Report 
 Provide specimen(s) for PCR (viral) test 
 Provide specimen for ELISA (antibody) test 
 Complete End‐of‐Study Survey 
 Complete DHCW Particip ation Questionnaire 
6.2 Patient Subjects 
The following is the schedule o f events for patients participat ing in the POC Offices.   
 
Visit  
Day POC Subjects 
Activities Performed in POC Offices 
4 Weeks Prior  
(5 minutes) Day ‐28 
(+/‐ 14 days)  Letter sent to providing st udy background to patient 
2 Weeks Prior  
(15 minutes) Day ‐14  
(+/‐ 14 days)  Potential subjects contacted to  introduce and determine interes t in the study 
 Obtain electronic consent signature 
 Complete Patient P re‐Visit Survey 
Visit  
(35 minutes) Day 1   Complete Start‐of‐Visi t Triage Case Report 
 Undergo POC Test 
 (Provision of Dental T reatment ‐ not part of  research protocol)  
 Complete Patient End‐of‐Visit Survey 
 Complete Patient Parti cipation Questionnaire 
 
  
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 24  The following is the schedule o f events for patients participat ing in the LAB Offices.   
 
Visit  
Day POC Subjects 
Activities Performed in LAB Offices 
4 Weeks Prior  
(5 minutes) Day ‐28 
(+/‐ 14 days)  Letter sent to providing st udy background to patient 
2 Weeks Prior  
(15 minutes) Day ‐14  
(+/‐ 7 days)  Potential subjects contacted to  introduce and determine interes t in the study 
 Obtain electronic consent signature 
 Complete Patient P re‐Visit Survey 
1 Week Prior  
(30 ‐ 60 minutes) Day ‐7  
(+/‐ 5 days)  Provide specimen for PCR (viral) test 
 Drop specimen off at a UPS store or UPS Dropbox 
Visit  
(20 minutes) Day 1   Complete Start‐of‐Visi t Triage Case Report 
  (Provision of Dental Treatment  ‐ not part of research protocol ) 
 Complete Patient End‐of‐Visit Survey 
 Complete Patient Parti cipation Questionnaire 
 
6.3 Unscheduled Visit 
 
Not applicable.  For dental pati ent participants, the study tak es place during 1 pati ent dental visit.  For 
Dental Healthcare Workers, data collection occurs at three spec ific times over a one-month period: start, 
mid-month, end of month. 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 25  7 STUDY PROCEDURES/EVALUATIONS 
In general, the study will include completion of COVID-19 triag e case reports, compl etion of COVID-19 
testing, and administration of perception and attitude surveys.   The DHCW Start-of-Visit, Mid-Visit and 
End-of-Visit and the Patient Start-of-Visit triage case report will include recording of temperatures and 
pulse oximeter reading for partici pants in both POC and LAB off ices.  During day 1, the dental visit, 
normal patient care will be prov ided to the patient subject.   
 
Group 1- DHCWs in POC Office 
 
Consent Process for Group 1- DHCWs in POC Offices 
Within 4 weeks prior to study initiation in the dental office, the National Dental PBRN Node Coordinator 
will consent the DHCWs in the participating office. The consent  will clearly outline participant expectations 
and offer the opportunity for potent ial participants to contact  the National Dental PB RN Node Coordinator 
for more information as needed.  D HCWs who elect to participate  will affirm their willingness to participate 
by signing the consent form.  
 
Study Procedures for Group 1- DHCWs in POC Offices  
Prior to study initiation (Up to 4 weeks prior) 
 Complete consent for all DHCW participants 
 
Day 1 
 Complete an electronic survey: DHCW Start of Study Survey   
o Questions include demographics , PPE used in the office, work p ractice controls used in 
the office, importance of triage and testing, importance of PPE  measures, perceptions of 
safety and comfort in the workpl ace, safety culture in the offi ce, SARS-CoV-2 testing 
preferences, dentists’ role in SARS-CoV-2 testing, and willingn ess to test in the office 
 Undergo a three-part COV ID-19 triage screening* 
o Symptom questions  
 Presence or absence of: 
 fever or chills 
 cough 
 shortness of breath or difficulty breathing 
 fatigue 
 muscle and body aches 
 headache 
 loss of taste 
 loss of smell 
 sore throat 
 congestion or runny nose 
 nausea or vomiting 
 diarrhea 
o Temperature check 
o Pulse oximeter reading 
 Complete two COVID-19 related tests** 
o SARS-CoV-2 POC test  ( administered by the PBRN practitioner or  designated 
investigator) 
 A nasal swab will be swept insi de the participant’s nose (not beyond the nares) to 
collect the specimen for  the SARS-CoV-2 test 
 The office staff will process t he specimen in the dental offic e 
o ELISA Antibody test (specimen co llected by the PBRN practition er, designated 
investigator or self) 
 A small lancet will create a fi nger prick to collect a small b lood sample for 
collection using a Mitra cartri dge (blood specimen collection d evice) 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 26   The Mitra cartridge will be pac kaged by the DHCW and placed in  the practice 
collection box to await shipment to Rutgers 
 The sample will be proc essed by the Public H ealth Research Ins titute (PHRI) Lab 
at Rutgers 
 
Mid-Study- Day 14 (+/- 7 days)  
 Undergo a COVID-19 triage screening in the office* 
 Complete a SARS-CoV-2 POC test **  (administered by the PBRN pr actitioner or designated 
investigator)  
o A nasal swab will sweep the in side of the participant’s nose ( not beyond the nares) to 
collect your specimen for the SARS-CoV-2 test 
o The office staff will pr ocess the specimen 
 
End of Study- Day 28 (+/- 7 days)  
 Undergo a three-part COV ID-19 triage screening* 
o Symptom questions 
o Temperature check 
o Pulse oximeter reading 
 Complete two SARS-CoV-2 tests** 
o SARS-CoV-2 POC test (administ ered by PBRN practitioner or desi gnated investigator) 
 A nasal swab will be swept insi de the participant’s nose (not beyond the nares) to 
collect the specimen for  the SARS-CoV-2 test 
 The office staff will process t he specimen in the dental offic e 
o ELISA Antibody test (specimen co llected by the PBRN practition er, designated 
investigator or self ) 
 A small lancet will create a fi nger prick to collect a small b lood sample for 
collection using a Mitra cartri dge (blood specimen collection d evice) 
 The Mitra cartridge will be pac kaged by the DHCW and placed in  the practice 
collection box to await shipment to Rutgers 
 The sample will be proc essed by the Public H ealth Research Ins titute (PHRI) Lab 
at Rutgers 
 Complete two electronic surveys:  
o DHCW End of Study Survey - Questions include importanc e of triage and testing, 
importance of PPE measures, perce ptions of safety and comfort i n the workplace, safety 
culture in the office, SARS-CoV- 2 testing preferences, dentists ’ role in SARS-CoV-2  
testing, willingness to test in the office, and vaccinations 
o DHCW Participation Survey - Questions explore perceptions  related to study participation 
including survey and testing logistics 
 
*If any aspect of the COVID-19 tr iage screening is positive wit hout any preexisting condition which could 
explain the positive screening (i.e.. a history of hay fever wh ich likely explains sneezing or a report of 
physical activity which likely explains muscle soreness), the D HCW will be referred to t heir primary care 
physician for further testing.  
 Positive screening includes hav ing one or more symptoms of unk nown origin 
 A positive temperature is con sidered greater  than 100.4 degree s F 
 A positive pulse oximeter is c onsidered when the blood oxygen saturation level is below 95% 
 
**If the POC COVID-19 test is posi tive, the DHCW may be dismiss ed from duties and instructed to 
consult with their primary care p rovider for further testing. 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Pr otocol Template v5.0–20190311  Page 27   
 
 
 
Group 2- Patients in POC Offices 
 
Consent Process for Group 2- Patients in POC Offices 
Three weeks (+/-  20 days) prior to visi t, patients will get an introductory/interest l etter, informing them 
about the study and that they may be receiving a phone call to determine their interest.  About two weeks 
prior to their scheduled dental visit, patients will be contact ed by the dental office to determine their 
willingness to participate in t he study.  Patients who indicate  interest will be sent an email link, which 
opens the consent.  Patients w ill be able to speak to the PBRN practitioner or approv ed staff member with 
any questions or seek clarifications.  The consent will clearly  outline participant expec tations and offer the 
opportunity for potentia l participants to c ontact the office fo r more information as needed.  Participants 
who elect to participate will a ffirm their willingness to parti cipate by clicking the “ I agree to take part in this 
study ” button at the end of the consent form.   
 
Study Procedures for Group 2- Patients in POC Offices  
Study participants will be a sked to do the following: 
 Two weeks before the dental visit 
o Complete and sign electronic consent 
o Complete an electronic survey: Patient Pre-Visit Survey   
 Questions explore p erceptions of safety and comfort, reasons f or delaying dental 
care, concerns about returning to  dental care, safety precautio ns valued, 
importance of triage and  testing, and demographics 
 Launched automatically after the completed consent 
 At the start of the Dental Visit 
o Undergo a COVID-19 triage screening in the office* 
 Screening includes symptom ques tions, temperature check, and p ulse oximeter 
reading 
o Complete COVID-19 POC test** (adm inistered by PBRN practitione r or designated 
investigator) 
 A nasal swab will be swept insi de the participant’s nose (not beyond the nares)  
to collect the specimen for the COVID-19 test 
 The PBRN Practitioner or their de signee will proc ess the speci men 
 At the End of the Dental Visit 
o Complete two electronic surveys  
 Patient End-of-Visit Survey   
 Questions explore per ceptions with testing preferences, PPE ob served, 
environmental controls observed , concerns about r eturning to de ntal 
care, safety precautions valued, i mportance of triage and testi ng, 
likelihood of reporting symptoms , dentist’s role in COVID-19 te sting and 
vaccinations 
 Patient Participation Survey  
 Questions explore perceptions r elated to study participation i ncluding 
survey and testing logistics 

Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Pr otocol Template v5.0–20190311  Page 28   
*If any aspect of the COVID-19 tr iage screening is positive wit hout any preexisting condition which could 
explain the positive screening (i.e.. a history of hay-fever wh ich likely explains sneezing or a report of 
physical activity which likely explains muscle soreness), appoi ntment will be postponed, and the 
participant will be referred to t heir primary care physician fo r further testing.  
 A Positive screening by reporti ng one or more symptoms of unkn own origin  
 A positive temperature is con sidered greater  than 100.4 degree s F 
 A positive pulse oximeter is c onsidered when the blood oxygen saturation level is below 95% 
 
**If the POC COVID-19 test is po sitive, the dental visit may be  postponed, and the positive patient 
participant will be instructed to c onsult with their primary ca re provider for fu rther testing.  
 
 
 
 
Group 3- DHCWs in LAB Offices 
 
Consent Process for Group 3- DHCWs in LAB Offices 
Within 4 weeks prior to study i nitiation in the dental office, the National Dental PBRN Node Coordinator 
will consent the DHCWs in the participating office. The consent  will clearly outline participant expectations 
and offer the opportunity for potent ial participants to contact  the National Dental PB RN Node Coordinator 
for more information as needed.  D HCWs who elect to participate  will affirm their willingn ess to participate 
by signing the consent form. 
 
Study Procedures for Group 3- DHCW in LAB Offices  
Prior to study initiation (Up to 4 weeks prior) 
 Complete consent for all DHCW participants 
 
Day 1 
 Complete an electronic survey: DHCW Start of Study Survey   
o Questions include demographics , PPE used in the office, work p ractice controls used in 
the office, importance of triage and testing, importance of PPE  measures, perceptions of 
safety and comfort in the workpl ace, safety culture in the offi ce, SARS-CoV-2 testing 
preferences, dentists’ role in SARS-CoV-2 test ing, and willingn ess to test in the office 
 Undergo a three-part COV ID-19 triage screening* 
o Symptom questions  
 Presence or absence of: 
 fever or chills 
 cough 
 shortness of breath or  difficulty breathing 
 fatigue 
 muscle and body aches 
 headache 
 loss of taste 

Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 29   loss of smell 
 sore throat 
 congestion or runny nose 
 nausea or vomiting 
 diarrhea 
o Temperature check 
o Pulse oximeter reading 
 Complete two COVID-19 related tests** 
o SARS-CoV-2 PCR viral test  
o Saliva (self-collected) and  tongue specimens (collected by PBR N practitioner, designated 
investigator or self)   
o ELISA Antibody test (specimen coll ected by PBRN practitioner, designated investigator 
or self) 
 A small lancet will create a fi nger prick to collect a small b lood sample for 
collection using a Mitra cartri dge (blood specimen collection d evice) 
 The Mitra cartridge will be pac kaged by the DHCW and placed in  the practice 
collection box to await shipment to Rutgers 
 The sample will be proc essed by the Public H ealth Research Ins titute (PHRI) Lab 
at Rutgers 
 
Mid-Study- Day 14 (+/- 7 days)  
 Undergo a COVID-19 triage screening in the office* 
 Complete a SARS-CoV-2 PCR Viral test**  
o Saliva (self-collected) 
 
End of Study- Day 28 (+/- 7 days)  
 Undergo a three-part COV ID-19 triage screening* 
o Symptom questions 
o Temperature check 
o Pulse oximeter reading 
 Complete two SARS-CoV-2 tests** 
o SARS-CoV-2 PCR viral test  
o Saliva (self-collected) and  tongue specimens (collected by PBR N practitioner, designated 
investigator or self)  
o ELISA Antibody test (specimen coll ected by PBRN practitioner, designated investigator 
or self) 
 A small lancet will create a fi nger prick to collect a small b lood sample for 
collection using a Mitra cartri dge (blood specimen collection d evice) 
 The Mitra cartridge will be pac kaged by the DHCW and placed in  the practice 
collection box to await shipment to Rutgers 
 The sample will be proc essed by the Public H ealth Research Ins titute (PHRI) Lab 
at Rutgers 
 Complete two electronic surveys:  
o DHCW End of Study Survey - Questions include importanc e of triage and testing, 
importance of PPE measures, perce ptions of safety and comfort i n the workplace, safety 
culture in the office, SARS-CoV- 2 testing preferences, dentists ’ role in SARS-CoV-2  
testing, willingness to test in the office, and vaccinations 
o DHCW Participation Survey - Questions explore perceptions  related to study participation 
including survey and testing logistics 
 
*If any aspect of the COVID-19 tr iage screening is positive wit hout any preexisting condition which could 
explain the positive screening (i.e., a history of hay-fever wh ich likely explains sneezing or a report of 
physical activity which likely explains muscle soreness), the D HCW will be referred to t heir primary care 
physician for further testing.  
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Pr otocol Template v5.0–20190311  Page 30   Positive screening includes hav ing one or more symptoms of unk nown origin 
 A positive temperature is con sidered greater  than 100.4 degree s F 
 A positive pulse oximeter is c onsidered when the blood oxygen saturation level is below 95% 
 
**If the lab processed SARS-CoV-2 test is positive, the DHCW ma y be dismissed from duties and 
instructed to consult with their primary care pro vider for furt her testing. 
  
 
 
Group 4- Patients in LAB Offices 
 
Consent Process for Group 4 - Patients in LAB Offices 
Three weeks (+/-  14 days) prior to a sch eduled dental visit, pa tients will get an introduct ory/interest letter, 
informing patients ab out the study and that t hey may be receivi ng a phone call to deter mine their interest.  
About two weeks prior to their scheduled dental visit, patients  will be contacted by the dental office to 
determine their willingness to participate in the study.  Patie nts who indicate inter est will be sent an email 
link, which opens the consent.  P atients will be able to speak to the PBRN practitioner or approved staff 
member with any questions or se ek clarifications.  The consent will clearly outline participant expectations 
and offer the opportunity for potent ial participants to contact  the office for more information as needed.  
Participants who elect to parti cipate will affirm their willing ness to participate by clicking the “ I agree to 
take part in this study ” button at the end of the consent form.   
 
Study Procedures for Group 4 - Patients in LAB Offices  
Study participants will be a sked to do the following: 
 Two weeks before the dental visit 
o Complete and sign electronic consent 
o Complete an electronic survey: Patient Pre-Visit Survey   
 Questions explore p erceptions of safety and comfort, reasons f or delaying dental 
care, concerns about returning to  dental care, safety precautio ns valued, 
importance of triage and  testing, and demographics 
 Launched automatically after the completed consent 
o Receive a saliva collection kit by mail 
 One week before the dental visit 
o Complete a COVID-19 saliva test 
 Spit into a tube  
 Package as directed 
o Drop off the completed test ki t at a UPS Store or drop-off box   
 At the start of the Dental Visit 
o Undergo a COVID-19 triage screening in the office* 
 Screening includes symptom ques tions, temperature check, and p ulse oximeter 
reading 
 At the End of the Dental Visit 
o Complete two electronic surveys  
 Patient End-of-Visit Survey   

Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Pr otocol Template v5.0–20190311  Page 31   Questions explore per ceptions with testing preferences, PPE ob served, 
environmental controls observed , concerns about r eturning to de ntal 
care, safety precautions valued, i mportance of triage and testi ng, 
likelihood of reporting symptoms , dentist’s role in COVID-19 te sting and 
vaccinations 
 Patient Participation Survey  
 Questions explore perceptions r elated to study participation i ncluding 
survey and testing logistics  
*If any aspect of the COVID-19 tr iage screening is positive wit hout any preexisting condition which could 
explain the positive screening (i.e., a history of hay-fever wh ich likely explains sneezing or a report of 
physical activity which likely explains muscle soreness), the a ppointment will be postponed, and the 
participant will be referred to t heir primary care physician fo r further testing.  
 A Positive screening by reporti ng one or more symptoms of unkn own origin 
 A positive temperature is con sidered greater  than 100.4 degree s F 
 A positive pulse oximeter is c onsidered when the blood oxygen saturation level is below 95% 
 
**If the lab processed SARS-CoV-2 test is positive,
 the dental visit may be postponed, and the positive 
patient participant will be instru cted to consult with their pr imary care provider  for further testing. 
 
 
 
Reporting and Notification 
The results of the POC, LAB, and/ Elisa test will be recorded i n the Testing Case Report  form in REDCap. 
The PI and/or Chief Protocol O fficer will notify the Practition er of test results.  The N ational Dental PBRN 
dentist member of the practice w ill be considered  the “Practiti oner” of the offi ce and assume the 
responsibility of notifying tes t results to the DHCWs and patie nts in the practice.  
For the purpose of this study, a  COVID-19 positive result is no t considered an adverse event though 
results of this test will be recorded.   
DHCW subjects who test antigen or viral positive or who triage positive without any preexisting medical 
condition will be instructed to s peak to their physicians for a  definitive diagnosis and follow-up.  If a 
DHCW is back to work in time for  the mid-study testing, the mid -study protocol will be followed.  Similarly, 
if a DHCW can return to work in  time for the end-of-study testi ng, the end-of-study protocol will be 
followed.  In either case, a follo w-up call by the PBRN practit ioner or designated inv estigator will be made 
approximately 1 week after the po sitive triage finding or test result to record any conf irmatory tests which 
were obtained based up on the advice of the DHCW’s physician.   
Patient subjects who are COVID-19  antigen or viral positive or who triage positive without any preexisting 
medical condition, will not be se en for their scheduled dental visit.   The subject will be referred to their 
physician for a definitiv e diagnosis and follow-up.     

Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 32    
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 33  7.1 Study Procedures/Evaluations 
The following study proce dures will be completed 
Group 1- DHCW Subjects in POC Offices 
 
Procedure and Evaluations   
Purpose Completed 
as Part of 
Study  
When Completed  
Who Completes  
Complete Consent  Complete 
informed 
consent  Yes  Prior to Enrollment  Study investigators meet with 
subjects and document consent in 
REDCap 
Start‐of‐study DHCW Survey  
 PPE used 
 Environmental Controls 
Used 
 Perception of Importance 
 Comfort 
 Safety 
 COVID‐19 Testing 
Preferences   
 Vaccination Opinions Collect baseline 
Outcomes measures Yes Start‐o
f‐Study(day 0) Data entered via REDCap self‐
administered survey 
Triage Case Reports  
 Collect COVID‐
19 screening 
data Yes  Start‐of‐Study  (Day 0) 
Mid‐Study  (Day 14) 
End of Study  (Day 28) Data entered into REDCap via eCRF 
by the Practitioner  
Testing Case Reports  
 Collect 
information on 
outcomes of COVID‐19 testing  Yes  Start‐of‐Study  (Day 0) 
Mid‐Study  (Day 14) 
End of Study  (Day 28) POC Test  
POC SARS‐CoV‐2 antigen test results 
entered into REDCap by the Practitioner or designated investigator for all DHCWs 
 
ELISA Ab test  
For Practitioner‐  Data entered into 
REDCap eCRF by the PI and/or Chief 
Clinical Officer  
 For other DHCWs‐  Data entered into 
REDCap eCRF by the PI and/or Chief 
Clinical Officer   
 
End‐of‐Study DHCW Survey  
 Collect 
payment 
information Yes End‐of‐Study(Day 28) Data entered via REDCap self‐
administered survey.  
Dental Health Care 
Participation Questionnaire Collect 
feasibility 
information on 
surveys and logistics Yes  End‐of‐Study  (Day 28)  Data entered via REDCap self‐
administered survey. 
 
 
 
  
 
  
 
 
 
  
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 34   
Group 2- Patient Subjects in POC Offices 
 
Procedure and Evaluations   
Purpose Completed 
as Part of 
Study  
When Performed  
How Completed  
Obtain Informed Consent  Complete 
informed 
consent  Yes 2 Weeks Prior (day ‐14+/‐14
days) 
 Electronic consent and signatures 
obtained prior to initiating Pre‐Visit 
Patient Survey 
Patient Start‐o f‐Visit Survey  
 Safety and Comfort  
 COVID‐19 Testing 
Preferences 
 Perception of Importance 
 Medical history 
Likelihood to report COVID‐19 symptoms  Collect 
outcome measures Yes 2 Weeks Prior (day ‐14 +/‐14 
days) Data entered via REDCap self‐
administered survey. 
Triage Case Report 
 Collect COVID‐
19 screening 
data Yes  Visit (day 1)  Data entered into REDCap via eCRF by 
the Practitioner or their investigator 
designee 
Testing Case Reports  
 Collect 
information on 
outcomes of COVID‐19 testing    Visit (day 1)  POC SARS‐CoV‐2 antigen test results 
entered into REDCap via eCRF by the 
Practitioner or their investigator designee 
Dental Procedures Performed  Maintain 
patient oral 
health NO  Visit  Completed by Dental Health Care 
Workers 
End‐of‐Visit Patient Survey  
 PPE observed in office 
 Environmental controls 
observed in office Collect 
outcome measures Yes Visit(day 1) Data entered via REDCap self‐
administered survey. 
Patient Participation 
Questionnaire Collect 
feasibility 
information on 
surveys and 
logistics Yes  End of Study  (Day 28)  Data entered via REDCap self‐
administered survey. 
 
 
 
 
  
 
  
 
  
 
 
 
  
 
  
 
  
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 35   
Group 3- DHCW Subjects in LAB Offices 
 
Procedure and Evaluations   
Purpose Completed 
as Part of 
Study  
When Completed  
Who Completes  
Complete Consent  Complete 
informed 
consent  Yes Prior to Enrollment Study investigators meet with 
subjects and document consent in 
REDCap 
Start‐of‐study DHCW Survey 
 PPE used 
 Environmental Controls 
Used 
 Perception of Importance 
 Comfort 
 Safety 
 COVID‐19 Testing 
Preferences   
 Vaccination Opinions Collect baseline 
Outcomes 
measures Yes  Start‐of‐Study  (day 0)  Data entered via REDCap self‐
administered survey 
Triage Case Reports 
 Collect COVID‐
19 screening 
data Yes  Start‐of‐Study  (Day 0) 
Mid‐Study  (Day 14) 
End of Study  (Day 28) Data entered into REDCap via eCRF 
by the Practitioner or designated 
investigator  
Testing Case Reports 
 Collect 
information on outcomes of 
COVID‐19 
testing  Yes  Start‐of‐Study  (Day 0) 
Mid‐Study  (Day 14) 
End of Study  (Day 28) PCR Viral and ELISA Ab tests 
For the Practitioner ‐ Data entered 
into REDCap eCRF by the PI and/or 
Chief Clinical Officer  
 For the other DHCWs‐ Data entered 
into REDCap eCRF b y the PI and/or 
Chief Clinical Officer  
End‐of‐Study DHCW Survey 
 Collect 
payment 
information Yes  End‐of‐Study  (Day 28)  Data entered via REDCap self‐
administered survey.  
Dental Health Care 
Participation Questionnaire Collect 
feasibility information on 
surveys and 
logistics Yes  End‐of‐Study  (Day 28)  Data entered via REDCap self‐
administered survey. 
 
 
 
 
 
 
 
  
 
  
 
  
 
  
 
  
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 36   
Group 4- Patient Subjects in LAB Offices 
 
Procedure and Evaluations   
Purpose Complete
d as Part 
of Study  
When Performed  
How Completed  
Obtain Informed Consent  Complete informed 
consent  Yes 2WeeksPrior (day‐
14 +/‐7 days) Electronic consent and signatures 
obtained prior to initiating Pre‐Visit 
Patient Survey 
Patient Start‐of‐Visit Survey  
 Safety and Comfort  
 COVID‐19 Testing Preferences 
 Perception of Importance 
 Medical history 
Likelihood to report COVID‐19 symptoms  Collect outcome 
measures Yes  2 Weeks Prior  (day‐
14 +/‐7 days)  Data entered via REDCap self‐
administered survey. 
Triage Case Report 
 Collect COVID‐19 
screening data Yes  Visit (day 1)  Data entered into REDCap by the PI 
and/or Chief Clinical Officer 
Testing Case Reports  
 Collect information 
on outcomes of 
COVID‐19 testing   Day Prior  (day ‐2 +/‐ 
2 days Saliva Viral SARS‐CoV‐2 test results 
entered into REDCap via eCRF by the 
Practitioner or their investigator 
designee 
Dental Procedures Performed  Maintain patient oral 
health NO  Visit  Completed by Dental Health Care 
Workers 
Patient End‐of‐Visit Survey  
 PPE observed in office 
 Environmental controls observed 
in office Collect outcome 
measures Yes  Visit (day 1)  Data entered via REDCap self‐
administered survey. 
Patient Participation Questionnaire  Collect feasibility 
information on 
surveys and logistics Yes  End of Study  (Day 
28) Data entered via REDCap self‐
administered survey. 
 
  
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 37  7.2 Laboratory Proc edures/Evaluations 
7.2.1 Clinical Laboratory Evaluations 
DHCW (dentists, hygienist, assist ants and front desk personnel)  and patient subjec ts will be tested for 
COVID-19.  DHCW will be administered POC, PCR Viral Test and/or  ELISA Antibody Test.  LAB patient 
subjects will be administered t he LAB test and POC patient subj ects will be administered the POC test.    
 POC Test 
(Antigen) DHCW 
PCR Viral Test DHCW 
ELISA Antibody Test 
Test Description    
Company BD Veritor System or Abbott 
COVID-19 antigen card test 
Kits Rutgers Rutgers 
Sample collected via Nasal swab  Saliva collection tube with 
buffer and/or tongue cells via 
cytology brush Capillary blood sample via 
Neoteryx Mitra Cartridge 
What is being Tested SARS-CoV-2 Nucleocapsid 
Antigen SARS-CoV-2 RNA IgG and IgM 
Test Administration 
(specimen collection) Nasal swab performed by 
PBRN Practitioner or 
designated investigator (not 
beyond the nares) Performed by PBRN 
Practitioner, designated 
investigator or self Performed by PBRN 
Practitioner, designated 
investigator or self 
Test Administration 
(specimen processing)  BD Veritor or Abbott COVID-
19 antigen card test 
performed by PBRN 
Practitioner or designated 
investigator Department of Oral Biology, 
Rutgers School of Dental 
Medicine and/or Genomics 
Laboratory, New Jersey 
Medicine School Mitra Cartridge is processed 
at ICPH-PHRI center, New 
Jersey Medical School, 
Newark, NJ 
Results Dichotomous (+ or -) Quantitative Quantitative 
 
With regard to the quality of the SARS-CoV-2 test specimen, the  following will be u sed to assess the 
quality of the specimen. 
 
  
POC Test  
PCR Viral Test  
ELISA Antibody Test 
Indication of Proper 
Processing The Veritor instrument will 
report if a sample is not able 
to be processed or control 
line on the Abbot COVID-19 
antigen card will not be able 
to be seen.  This feedback 
will be used to identify 
insufficient training or 
unanticipated problems.   The Oral Biology Lab and/or 
Genomics Laboratory will 
report if a sample is not able 
to be processed.  This 
feedback will be used to 
identify insufficient training 
or unanticipated problems.   ICPH will report if a sample is 
not able to be processed.  
This feedback will be used to 
identify insufficient training or 
unanticipated problems.   
7.2.2 Specimen Preparation,  Handling, and Storage 
The following details specim en preparation, handling and storag e.  
 POC Test PCR Viral Test ELISA Antibody Test 
Sample Collection & Shipping 
Sample 
Collection 
Materials Nasal swab included in 
BD Veritor or Abbott 
COVID-19 antigen card 
system Saliva collection kit via 
Spectrum and/or Tongue 
cell collection kit via Oral 
Biology Laboratory Capillary blood sample via Mitra Cartridge 
Storage of 
Specimen 
Collection 
Supplies and 
Test Kits National Dental PBRN 
Office after kits are mail to 
them from the Clinical 
Research Center at the 
Rutgers School of Dental 
Medicine National Dental PBRN 
Office after kits are mail to 
them from the Clinical 
Research Center at the 
Rutgers School of Dental 
Medicine National Dental PBRN Office  after kits are mail to 
them from the Clinical Research Center at the 
Rutgers School of Dental Medicine 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 38  Transport 
Media Not applicable (POC 
Test) Buffer solution Sponge with capillary blood is transported with 
desiccant 
Packaging 
Specimen for 
Shipping Not applicable (POC 
Test) Sealed biohazard plastic 
bag placed into a 95 kPa 
bio-hazard bag  with 
absorbent which is placed 
into a UN3373 Category B 
certified box. Post sampling, the clos ed Mitra Cartridge is  
inserted into sealed specim en bag which contains a 
decedent that absorbs moisture, and inserted in a 
shipping UN3373 Category B certified box. 
Sample Processing (Performing the Test) 
Processing 
Supplies Included in point-of-care 
BD Veritor or Abbott 
COVID-19 antigen card RNA extraction, followed 
by RT-PCR 96 well plate, ELISA reagents 
Processing 
Time 15 minutes About four hours Overnight extraction at 4C, followed by automated 
ELISA 
Conditions for Stability a nd Transport Condition 
Stability 
prior to Use  No special storage 
conditions required No special storage 
conditions required No special storage conditions required  
Dry blood on Mitra Cartridge stable at room 
temperature for 28 days. 
Stability 
during 
shipping Not applicable (POC 
Test) Yes due to transport media Yes due to desiccant 
Storage prior 
to 
processing Not applicable (POC 
Test) Oral Biology Laboratory 
and/or Genomics 
Laboratory PHRI Laboratory 
Stability 
prior to 
processing Stable at room 
temperature Stable at room 
temperature Stable at room temperature 
Tracking    
Labeling Not applicable (POC 
Test) Specimen ID (bar code) 
Subject ID (bar code) 
Subject Name 
Date of Specimen Specimen ID (bar code) 
Subject ID (bar code) 
Subject Name 
Date of Specimen 
Tracking of 
Specimen 
Collection 
Kits Not applicable (POC 
Test) REDCap System and/or 
Excel Worksheet REDCap System and/or Excel Worksheet  
Tracking of 
Tests 
Administered  Completion of REDCap 
SARS-CoV-2 Test Order 
and Results Form (which 
enables the generation of 
a Specimen Tracking 
Log) Completion of REDCap 
SARS-CoV-2 Test Order 
and Results Form (which 
enables the generation of 
a Specimen Tracking Log) Completion of REDCap SARS-CoV-2 Test Order 
and Results Form (which enables the generation of 
a Specimen Tracking Log) 
Results 
Processing 
Time 15 minutes Results are available 
within 1 week. Results are available within 1 week 
Recording 
Results in 
REDCap Via posting in REDCap by 
PBRN Practitioner or 
designated investigator  Via secure e-mail and web 
site and then posted into 
REDCap by the Rutgers 
research staff  
 Via secure e-mail and then posted into REDCap by 
the Rutgers research staff  
 
Notifying 
participants National Dental PBRN 
Practitioner or designated 
investigator PBRN Practitioner 
results - by the PI and/or 
Clinical Chief  
DHCW and Patient 
results - by the National 
Dental PBRN Practitioner 
or designee PBRN Practitioner results - by the PI and/or 
Clinical Chief  
DHCW and Patient results - by the National Dental 
PBRN Practitioner or des ignated investigator 
Reporting to 
State 
Department 
of Health PI, Chief Clinical Officer, 
PBRN Practitioner or 
designated investigator Genomics Laboratory Not Applicable 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 39  7.2.3 Specimen Shipment 
Saliva for LAB, and nasal swab fo r the PCR Viral Test specimens  are collected and immediately placed 
into a preservative.  The Mitra Ca rtridge includes a desiccant or sample preservation.  All can be stored at 
room temperature for at least one week. 
  
POC Test  
PCR Viral Test  
ELISA Antibody Test 
Shipment Method 
and Frequency Not applicable   Samples will be obtained from 
subjects Monday and 
Wednesday and sent to the 
Rutgers School of Dental 
Medicine via UPS or Federal 
Express.   Specimens will be mailed via UPS or 
Federal Express.   
 
 
Packaging Specimen 
for Shipping Not applicable (POC 
Test) Specimens are placed into 
biohazard plastic bag, sealed 
then placed into a 95 kPa bio-
hazard bag  with absorbent, 
sealed and then placed into a 
UN3373 Category B certified 
box. Post sampling, the closed Mitra Cartridge 
is  inserted into sealed specimen bag 
which contains a decedent that absorbs 
moisture then placed into a 95 kPa bio-
hazard bag with absorbent and inserted in 
a shipping UN3373 Category B certified 
box. 
Shipping Address Not applicable Rutgers University 
School of Dental Medicine 
110 Bergen Street 
Newark, NJ  07103 Rutgers University 
School of Dental Medicine 
110 Bergen Street 
Newark, NJ  07103 
Contact Information 
for Laboratory 
Personnel Not applicable Dr. Daniel Fine 
Phone:  (973) 972-7056 
finedh@sdm.rutgers.edu 
Dr. Patricia Soteropoulos 
Phone: (973) 972- 3890 
soteropa@njms.rutgers.edu 
 Dr. Maria Gennaro 
Phone:  (973) 854-=3210 
Marila.gennaro@rutgers.edu 
Days and Times 
shipments are 
allowed Not applicable Monday thru Friday 
9:00 am to 5:00 pm Monday thru Thursday 
9:00 am to 5:00 pm 
Labeling 
Requirements for 
Specimen Shipping Not applicable Subject Number, Subject 
Name, and Collection Tube 
ID/Bar Code Subject Number, Subject Name and Mitra 
Cartridge ID/Bar Code 
Special Instruction 
for Specimen 
Collection No special instructions Subject should not eat or drink 
for 30 minutes prior to saliva 
and tongue cell specimen 
collection Clean area for finger prick with alcohol 
gauze prior to pricking finger 
Special Instructions 
for Specimens for 
Shipment  (i.e., dry 
ice, wet ice) Not applicable No special instructions No special instructions 
Completion of 
Specimen-Tracking 
Log Completion of 
REDCap COVID-19 
Test Order and 
Results Form (which 
enables the generation 
of a Specimen 
Tracking Log) Completion of REDCap 
COVID-19 Test Order and 
Results Form (which enables 
the generation of a Specimen 
Tracking Log) Completion of REDCap COVID-19 Test 
Order and Results Form (which enables 
the generation of a Specimen Tracking 
Log) 
 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 40  8 ASSESSMENT OF SAFETY 
8.1 Definitions and Specifi cations of Safety Parameters 
Safety monitoring for this study will focus on unanticipated pr oblems involving risks to participants, 
including unanticipated problems that meet the definition of a serious adverse event.   
 
Event  Definition  Form Who 
completes 
REDCap 
form  Time Frame 
For Reporting 
to sIRB  Additional 
Reports  
 
Unanticipated 
Problems  Any problem or event which was:  
1. Unexpected (in nature, severity, or 
frequency)  
AND 2. Is related or possibly related to 
participation in the research  
AND  3. Reflects new increased risk to the 
subjects  Unanticipated 
Problem Form    
 
    National 
Dental PBRN Node Coordinator or Node 
Director If the UP is also 
an SAE, submit the UP form within 5 working days to the CIRB directly  
 
If the UP is not an SAE, submit to CIRB and to NIDCR within 2 weeks of 
becoming aware 
of the problem.  
 
  
 
   NIDCR via 
Rho Product Safety (Simultaneously with IRB) 
Adverse Event  When an investigator receives a report of an 
external adverse event, the investigator should review the report and assess whether it identifies the adverse event as being: 
1. unexpected; 
2. related or possibly related to 
participation in the research; and 
3. serious or otherwise one that 
suggests that the research places subjects or others at a greater risk of physical or psychological harm than was previously known or recognized.  
 
If the responses to the above are “yes” then it should be reported as an unanticipated problem (or an SAE, if the answer to 3. Is “yes.”)  Adverse Events 
Form National 
Dental PBRN Node Coordinator or Node Director Only required to 
submit to CIRB if UP or SAE.  Not required 
unless UP or SAE. 
Serious Adverse 
Event Serious adverse event (includes serious 
adverse drug or biological experience and unanticipated adverse device experiences under FDA regulations) is any adverse event temporally associat ed with the subject's 
participation in research that meets any of 
the following criteria: 
• Results in death • Is life-threatening (places the subject at 
immediate risk of d eath from the event 
as it occurred) 
• Requires inpatient hospitalization or 
prolongation of existi ng hospitalization 
• Results in a persistent or significant 
disability/incapacity 
• Results in a congenital anomaly/birth 
defect 
• Any other adverse event that, based upon 
appropriate medical judgment, may 
jeopardize the subject's health and may require medical or surgical intervention Unanticipated 
Problem Form AND Serious Adverse Events Form National 
Dental PBRN Node Coordinator Submit SAE form 
within 24 hours if incident caused death or life threatening injury or within 72 hours 
for all other results 
to the NIDCR safety committee (rho_productsafet
y@rhoworld.com ).  NIDCR via 
Rho Product Safety (Simultaneously with IRB), Regional IRB 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 41  to prevent one of the other outcomes 
listed in this definition.  
Protocol 
Deviation/ 
Violation  Deviations: Any change, divergence, or 
departure from the study procedures 
described in the IRB-approved clinical 
protocol  Violation: Any deviation from the sIRB approved protocol that may affect the subject's rights, safety , or well-being and/or 
the completeness, accur acy and reliability of 
the study data Protocol Deviation/ 
Violation Form National 
Dental PBRN 
Node 
Coordinator or Node Director 10 business days 
from the date of 
discovery Other study 
Sites 
 
Monthly to NIDCR on the first of the month via NIDCR Reports 
@rhoworld.com 
 
Study procedures are limited to surveys and collection of biosp ecimens: saliva samples, capillary blood 
samples via finger prick, super ficial tongue scraping, and nasa l swab (not beyond the nares) samples.  
We therefore expect few, if any s tudy related se rious adverse e vents (SAEs).  In the rare event that a 
SAE were to occur, an Unanticipat ed Problem form would be compl eted, and SAE reporting timelines 
would be followed.  
8.1.1 Unanticipated Problems 
The Office for Human Research Pro tections (OHRP) considers unan ticipated problems involving risks to 
subjects or others to include , in general, any incident, experi ence, or outcome that meets all of the 
following criteria: 
 unexpected in terms of nature, s everity, or frequency given (a ) the research procedures that are 
described in the protocol-related documents, such as the sIRB-a pproved research protocol and 
informed consent document; and (b)  the characteristics of the s ubject population being studied; 
 related or possibly related to participation in the research ( “possibly related” means there is a 
reasonable possibility that the in cident, experie nce, or outcom e may have been caused by the 
procedures involved in the research); and 
 suggests that the research place s subjects or others at a grea ter risk of harm (including physical, 
psychological, economic, or social harm) than was previously kn own or recognized. 
8.1.2 Serious Adverse Events 
A serious adverse event (SAE) i s one that meets one or more of the following criteria: 
 Results in death 
 Is life-threatening (places the subject at immediate risk of d eath from the event as it occurred) 
 Results in inpatient hospitalization or prolongation of existi ng hospitalization 
 Results in a persistent or si gnificant disability or incapacit y 
 Results in a congenital anomaly or birth defect   
 An important medical event that m ay not result in death, be li fe threatening, or require 
hospitalization may be consider ed an SAE when, based upon appro priate medical judgment, the 
event may jeopardize the subject and may require medical or sur gical intervention to prevent one 
of the outcomes listed in this definition. 
 
If a SAE becomes known, the Natio nal Dental PBRN Practitioner o r designated investigator will 
immediately notify the National D ental PBRN Node Coordinator wh o will then notify study PI. The 
National Dental PBRN Node Coord inator will record the event in the REDCap Unanticipated Problem 
form and Serious Adverse Event F orm based upon information obta ined.   
8.1.3 Protocol Deviations/Violations 
As the purpose of this pilot is to  determine if the study windo ws are appropriate, activities taking place 
outside of a specified window w ill not be considered a protocol  deviation or violation.  In addition, any 
missed or incomplete surveys or  forms will not be considered pr otocol deviation or violation as these are 
outcome measures for the pilot study.  
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 42  8.2 Reporting Procedures 
8.2.1 Unanticipated Problem Reporting  
Incidents or events that meet t he Office of Human Research Prot ection (OHRP) criteria for UPs require 
the creation and completi on of a UP report form.   
 
OHRP recommends that investigator s include the following inform ation when reporting an adverse event, 
or any other inciden t, experience, or outc ome as an unanticipat ed problem to the sIRB: 
 appropriate identifying informat ion for the research protocol,  such as the title, investigator’s name, 
and the sIRB project number; 
 a detailed description of the adverse event, incident, experie nce, or outcome;  
 an explanation of the basis for determining that the adverse e vent, incident, experience, or 
outcome represents an unanticipated problem;  
 a description of any changes to  the protocol or other correcti ve actions that have been taken or 
are proposed in response  to the unanticipated problem. 
 
To satisfy the requirement for prompt reporting, UPs will be re ported that are no t SAEs will be reported 
using the following timeline:   
 Unanticipated problems that a re SAEs will be reported to the s IRB as soon as possible, and no 
later than within 5 business day s of the investigator becoming aware of the event.  
 Any other UP will be reported to  the sIRB as so on as possible but within 10 business days of the 
investigator becoming aware of the problem. 
 All UPs should be reported to appropriate institutional offici als (as required by  an institution’s 
written reporting procedures) , the supporting agency head (or d esignee), and OHRP within one 
month of the sIRB’s receipt o f the report of the problem from t he investigator. 
 
All unanticipated problems will be reported to NIDCR concurrent ly with reporting  to the sIRB. These 
reports will be made to NIDCR’s c entralized reporting system vi a the Clinical Research Operations and 
Management Support (CROMS) contractor. 
● Product Safety Fax Li ne (US):  1-888-746-3293 
● Product Safety Fax Line (I nternational):  919-287-3998 
● Product Safety Email:  rho_productsafety@rhoworld.com  
General questions ab out SAE reporting can be  directed to the Rh o Product Safety Help Line (available 
8:00AM – 5:00PM Eastern Time):   
● US:  1-888-746-7231 
● International: 919-595-6486   
 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 43  9 STUDY OVERSIGHT 
The PI will be respons ible for study overs ight, including monit oring safety, ensuring that the study is 
conducted according to the prot ocol and ensuring data integrity .  The PI will review the data for safety 
concerns and data trends at regul ar intervals and will promptly  submit reportable events to the sIRB and 
NIDCR that arise during  the conduct of the study. 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 44  10 CLINICAL SITE MONITORING 
No outside clinical site monito ring will be employed for this s tudy. The PI and staff will closely monitor 
adherence to the study protocol and study processes throughout the study. They will ensure that quality 
management activities occur and w ill evaluate study processes a nd documentation based on the 
International Council for Harmon isation (ICH), E6: Good Clinica l Practice guidelines (GCP), and internal 
quality management plans. The NID CR reserves the right to condu ct independent clinical site monitoring 
as necessary. 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 45  11 STATISTICAL CONSIDERATIONS  
This is a feasibility study to a ssess feasibility to conduct st udy procedures and refine trial study logistics.  
No sample size calculations are being performed.   
11.1 Final Analysis Plan 
Data to be collected includes:   
 
Item  
Type of Variable 
Willingness to Participate 
 Dentist, Hygienist, Assi stant and Front Desk 
personnel willing to participate 
 Patient willingness to participate   Willingness to participate (Binary – Yes/No) 
 
Triage Survey   Ease of Administration ( 3 point Likert Scale) 
o Very easy to complete surv ey due to administration 
method 
o Easy to administer com plete survey due to 
administration method 
o Not easy to complete s urvey due to survey 
administration method 
 Completeness (Binary – Yes/No) 
 Question understandability  (3 point Likert Scale) 
o Very clear to understand 
o Understandable with some cl arification provided by 
the administrator 
o Not clear to understand 
Safety Perception Survey  
 Start‐of‐Study DHCW Survey 
 End‐of‐Study DHCW Survey 
 Start‐of‐Visit Patient Survey 
 End‐of‐Visit Patient Survey   Administration method (3  point Likert Scale) 
o Very easy to complete surv ey due to administration 
method 
o Easy to complete survey  due to administration 
method 
o Not easy to complete surve y due to administration 
method 
 Completeness (Binary – Yes/No) 
 Question understandability  (3 point Likert Scale) 
o Very clear to understand 
o Understandable with some cl arification provided by 
the administrator 
o Not clear to understand 
Testing Logistics 
 LAB – saliva SARS‐CoV‐2 viral test 
 POC – BD Veritor COVID‐19 antigen test 
 PCR viral SARS‐CoV‐2 test 
 ELISA antibody SARS‐CoV‐2 test  Specimen Collection  (3 point Likert Scale) 
o Very easy to collect 
o Easy to collect 
o Not easy to collect 
 Specimen preparation for shi pping  (3 point Likert Scale) 
o Very easy to prepare 
o Easy to prepare 
o Not easy to prepare 
 Specimen storage  (Bin ary – Easy/Not Easy) 
o Easy to Store 
o Not easy to store 
 Timeliness of results  (3 point Likert Scale) 
o Very timeless access to results 
o Timely access to results 
o Access to results not timely 
 Reporting of results  (3 point Likert Scale) 
o Very easy to access results 
o Easy to access results 
o Not easy to access results 
Testing Case Report   Completeness (Binary – Yes/No) 
 
Descriptive statistics (frequ encies) for all variables will be performed.   
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 46  12 SOURCE DOCUMENTS A ND ACCESS TO SOURCE  DATA/DOCUMENTS 
All study survey information w ill be captured electronically an d stored on secure, encrypted Rutgers 
University servers.   
 Patient consents will be captur ed and recorded directly into t he REDCap system. 
 All Patient and DHCW surveys w ill be recorded directly into RE DCap via the following REDCap  
forms:  
 
DHCW Participants  Patient Participants 
Start‐of‐Study DHCW Surv ey  Triage Case Report 
Triage Survey Case Report  Pre‐Visit Patient Survey
End‐of‐Study DHCW Survey  End‐of‐Visit Patient Survey 
DHCW Feasibility Study Participation Questionnaire  Patient Feas ibility Study Partici pation Questionnaire 
Testing Case Report  Testing Case Report 
 
 Testing results will be captured in the REDCap Te sting Case Re port in the following ways: 
 
   
POC  PCR  
ELISA 
Original Source 
Document N/A – Results appear on BD 
Veritor Screen or Abbott COVID‐
19 antigen test card and directly 
recorded into REDCap  Excel Spreadsheet posted onto 
SDM PREDICT box drive Excel Spreadsheet posted onto SDM 
PREDICT box drive 
Storage of Original Source Document Not Applicable  Electroni cally stored on Rutgers 
server Electronically stored on Rutgers 
server 
Responsibility for Entering into REDCap National Dental PBRN Practitioner 
or their investigator designee Rutgers PI, Clinical Protocol Chief 
or their designee Rutgers PI, Clinical Protocol Chief or 
their designee 
Verification of Correct Entry into REDCap Not Applicable  PI or Chief  of Clinical Protocol or 
their designee PI or Chief of Clinical Protocol or 
their designee 
 
 At the end of the study, deidentif ied data will be provided to  the National Coordinating Center. 
All paper-based study source doc uments will be maintained in th e Rutgers School of Dental Medicine 
Clinical Research Center which i s located on the D Level of the  Dental School Building.  All documents 
will be secured in a locked file  cabinet in the center.  Access  to the Clinical Research Center is limited to 
research center personnel via a card reader. 
Study staff will maintain  appropriate medical  and research reco rds for this study, in compliance with ICH 
E6, Section 4.9 and regulatory and institutional requirements f or the protection of confidentiality of 
participants. Study staff will permi t authorized representative s of NIDCR and regulatory agencies to 
examine (and when requi red by applicable la w, to copy) research  records for the purposes of quality 
assurance reviews, audits, and evaluation of the study safety, progress, and data validity.   
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 47  13 QUALITY CONTROL AND QUALITY ASSURANCE 
Quality Management (QM) measures  will occur throughout this stu dy to ensure adherence to protocol and 
collection of complete and accura te data.  QM activities includ e those measures done as part of daily 
standard operating procedures b y staff at each site and by the data management controls built into the 
PREDICT REDCap.  QM activities w ill include activi ties undertak en at defined intervals to ensure that all 
study personnel have undergone training prior to initiating the  protocol, QM activities are occurring, and 
study-related document s are up-to-date.   
Staff Training 
 
Training of all staff will be condu cted and recorded in trainin g logs.  Each staff member has been 
identified by role.  Records of c ompleted training will be main tained by the node coor dinator on the NCC 
Hub.   
 
 
Training Modules  Who Will be Trained 
Human Subjects, HIPAA   All Study Personnel 
General Clinical Research Training  
(Human Subjects, HIPAA)  PI, Chief of Clinical Protocol, P BRN practitioners and designat ed 
investigators 
General Overall  
(Study Purpose, Goals and Protocol)  All Study Personnel 
 
REDCap System Training   National Dental PBRN Practitione rs and Designated Investigators  
Daily Operating Procedures 
The PI and the Chief of Clinical Protocol will follow the REDCa p dashboard to ensure compliance with 
study procedures.  The dashboard exhibits r ed indicators for in struments which have been started and 
not completed, yellow indicators  for instruments which have bee n completed and no t verified and green 
indicators for instruments whic h have been completed and review ed.  The PI or Chief of Clinical Protocol 
will be responsible for reviewing each instrument and changing the status from unverified to verified.  Any 
issues with compliance with the study protocol identified by th e PI or Chief of Clinical Protocol will be 
reviewed with the National Dental  PBRN Practitioner and be used  to identify any unanticipated problems 
and develop/implement any necessa ry corrective action plans. 
Subject Completion Review 
 
As this is a feasibility study, rev iews of surveys and case rep orts to ensure comp leteness will not be 
completed, rather the number/perc entage of incomplete surveys a nd forms will be analyzed as an 
outcome measure.  Consent forms w ill be reviewed for completene ss at the mid-study visit for DHCW 
subjects and as part of the end-of -visit survey for patient sub jects. 
Data Management Controls 
 
REDCap is a rich system which e nables privileging, required dat a element entry and required data 
validation to be embedded into daily operations.   
 Privileging:   Every study staff member will be assigned a role  which carrie s specific 
read/write/edit/delete privil eges.  Staff member will be assign ed a role providing minimal rights 
sufficient to perform his /her responsibilities. 
 Structured Data:   Whenever possible, d ata will be collected via structured data  responses rather 
than free-text.  Structured data requires a respondent to check  a valid response.   
 Data Validation:   Data fields will be established limiting responses to those t hat are reasonable.  
For example, year of birth woul d have a range of 2002 (correspo nding to age 18 – the youngest 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 48  eligible) to 1920 (correspondi ng to age 100 – more than suffici ent to cover the age range of 
individuals having impacted 3rd molars extracted.) 
 Required Fields:   Whenever appropriate, fields have been made required so as to  ensure 
completed forms and questionnaires. 
 
Structured responses are requir ed for the CRFs so only valid re sponses can be recorded.  In addition, 
REDCap has been programmed with all responses being required at  time of completion which will trigger 
an error message, but subjects c an save their responses without  all responses being completed. 
Validation rules are em ployed where possible. 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 49  14 ETHICS/PROTECTION OF HUMAN SUBJECTS 
14.1 Ethical Standard 
The investigator will ensure tha t this study is conducted in fu ll conformity with the principles set forth in 
The Belmont Report: Ethical Princ iples and Guidelines for the P rotection of Human Subjects of Research, 
as drafted by the US National Com mission for the Protection of Human Subjects of Biomedical and 
Behavioral Research (April 18, 1979) and codified in 45 CFR Par t 46 and/or the ICH E6.  
14.2 Institutional Review Board 
The protocol, informed consent fo rm(s), recruitment materials, and all participant materials will be 
submitted to the sIRB for review  and approval. Approval of both  the protocol and the consent form(s) 
must be obtained before any parti cipant is enrolled.  Any amend ment to the protocol w ill require review 
and approval by the sIRB before  the changes are implemented in the study.   
14.3 Informed Consent Process 
Informed consent is a process t hat is initiated prior to the in dividual agreeing to participate in the study 
and continues throughout study par ticipation. Extensive discuss ion of risks and possible benefits of study 
participation will be provided to participants and their famili es, if applicable. A conse nt form describing in 
detail the study procedures and risks will be given to the part icipant. Consent forms will be sIRB-
approved, and the participant is required to read and review th e document or have the document read to 
him or her. The investigator or their investigator designee wil l explain the research study to the participant 
and answer any questions that may arise.  
All DHCWs and patient participants will review and electronical ly sign the informed consent document 
prior to any study-related asse ssments or procedures.  For LAB and POC patient subjects, an electronic 
consent and signature will be obtai ned before the Pre-Visit-Tri age survey is completed.   
Participants will be given the opportunity to d iscuss the study  with their surrogates or think about it prior to 
agreeing to participa te. They may withdraw consent at any time throughout the course of the study. A 
copy of the signed informed consent document will be given to p articipants for their records. The rights 
and welfare of the parti cipants will be protec ted by emphasizin g to them that the quality of their clinical 
care will not be adverse ly affected if they decline to particip ate in this study. 
The consent proce ss will be documented in  the clinical or resea rch record.   
14.4 Exclusion of Women, Minorit ies, and Children (Special Popu lations) 
Women and minorities will be elig ible to participate.  Children  less than 18 years will not be able 
participate. 
14.5 Subject Confidentiality 
Subject confidentiality is stric tly held in trust by the invest igators, study staff, and  the study sponsor(s) and 
their agents. This confidentia lity is extended to cover testing  of biological samples and genetic tests in 
addition to any study information relating to participants. 
The study protocol, documentati on, data, and all other informat ion generated will be held in strict 
confidence. No information conc erning the study, or the data wi ll be released to any unauthorized third 
party without prior written a pproval of the study sponsor. 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 50  The study monitors or other autho rized representatives of NIDCR  may inspect all study documents and 
records required to be maintai ned by the investigator, includin g but not limited to, medical records (office, 
clinic, or hospital) for the st udy participants. The clinical s tudy site will permit acc ess to such records. 
Certificate of Confidentiality  
To further protect the privacy o f study participants, the Secre tary, Health and Human Services (HHS), has 
issued a Certificate of Confident iality (CoC) to all researcher s engaged in biomedical, behavioral, clinical, 
or other human subjects researc h funded wholly or in part by th e federal government. R ecipients of NIH 
funding for human subjects researc h are required to protect ide ntifiable research i nformation from forced 
disclosure per the terms of the NIH Policy (https://humansubjec ts.nih.gov/coc/index  - Certificates of 
Confidentiality (CoC ) – Human Subjects).  As set forth in   45 CFR Part 75.303(a)  and NIHGPS Chapter 
8.3, recipients conducting NIH-suppo rted research covered by this Policy are required to establish and 
maintain effective internal cont rols (e.g., policies and proced ures) that provide reasonable assurance that 
the award is managed in complianc e with Federal statutes, regul ations, and the terms and conditions of 
award. It is the NIH policy that i nvestigators and others who h ave access to researc h records will not 
disclose identifying information except when the participant co nsents or in certain in stances when federal, 
state, or local law or regulation requires disclosure. NIH expe cts investigators to inform research 
participants of the protections an d the limits to protections p rovided by a Certificate  issued by this Policy. 
NIH Data Sharing Policies  
As described in section 17, it i s NIH policy that the results a nd accomplishments of the activities that it 
funds should be made available to  the public (se e https://grant s.nih.gov/policy/shri ng.htm - NIH Sharing 
Policies and Related Guidance on NI H-Funded Research Resources) .  PIs and funding recipient 
institutions will ensure that all mechanisms used to share data  include proper plans and safeguards to 
protect the rights and privacy o f individuals who participate i n NIH-sponsored research.  
14.6 Future Use of Stored Specime ns and Other Identifiable Data  
No residual specimens will be ma intained after this project is completed.  All Identifiable data will be 
destroyed 6 years after the study is completed.     
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 51  15 DATA HANDLING AND RECORD KEEPING 
The study PI is responsible for ensuring the accuracy, complete ness, legibility, and ti meliness of the data 
reported. All source documents should be completed in a neat, l egible manner to ensure accurate 
interpretation of data. The investigators will maintain adequat e case histories of study participants, 
including accurate case report fo rms (CRFs), and source documen tation. 
15.1 Data Management Responsibilities 
 
The PIs in collaboration with the NCC will review reports of da ta completeness and accuracy as well as 
protocol compliance on an ongoing  basis throughout the study. 
15.2 Data Capture Methods 
 
Other than the Testing Case Repo rt, all data for the study be e lectronically captured .  Various devices will 
be used including: 
 Laptop and desktop computers to  complete surveys and forms dir ectly into REDCap, the 
electronic data capture system for the study 
 iPads to complete surveys, form s and capture electronic signat ures directly into REDCap 
 Bar code scanner to label study specimens 
 Patients will use their own comp uter of personal electronic dev ice to sign the consent form and answer 
the pre-visit survey.  DHCW will use their own co mputer, electr onic device, an office computer electronic 
device or the study provided electronic pads for consents.  All  other forms and surveys to be completed 
DHCW or patient subjects by usi ng study provided electronic pad s.   
 
REDCap will be used to collect and maintain all study data.   
 
 DHCW 
Method of Collection  DHCW
Entered By 
Whom PATIENTS
Method of 
Collection PATIENTS
Entered by Whom 
Surveys Survey administered 
via REDCap with 
responses entered 
directly into REDCap By study 
participant on 
office iPad Survey administered 
via REDCap with 
responses entered 
directly into 
REDCap By study participant 
on computer or 
other electronic 
device at home 
Triage Survey 
Case Report Survey administered 
via REDCap form with 
responses entered 
directly into REDCap By PBRN 
Practitioner or 
Investigator 
designee REDCap form  By PBRN 
Practitioner or 
Investigator 
designee 
POC Test Results 
Case Report Data from Veritor 
Reader or Abbott 
COVID-19 Ag Card By PBRN 
Practitioner or 
Investigator 
designee Data from Veritor 
Reader or Abbott 
COVID-19 Ag Card By PBRN 
Practitioner or 
Investigator 
designee 
PCR Test Results 
Case Report Data entered directly of 
e-mail of results into 
REDCap Form upon 
receipt of secure e-mail 
from lab Rutgers PI, Chief 
of Protocol or 
Designee Data entered 
directly into 
REDCap Form upon 
receipt of secure e-
mail from lab Rutgers PI, Chief of 
Protocol or 
Designee 
ELISA Antibody 
Test Results Case 
Report Data entered directly 
from e-mail of results 
into REDCap Form 
upon receipt of secure 
e-mail from lab Rutgers PI, Chief 
of Protocol or 
Designee Data entered 
directly into 
REDCap Form upon 
receipt of secure e-
mail from lab Rutgers PI, Chief of 
Protocol or 
Designee 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 52  All study data will be centrally stored on t he Rutgers REDCap d ata management system, and study-
related documentation will be ma intained on RSDM PREDICT Box dr ive. REDCap is a secure web 
application which is password pr otected and compliant with 21 C FR Part 11. Study data and 
documentation will be available  to the study PI and core person nel in real time, per allowable 
permissions.   
 
15.3 Types of Data 
Types of data to be collected incl ude DHCW and patient percepti ons and attitudes, medical history, 
COVID-19 like symptoms (of unkno wn origin), temperature, pulse oximeter readings and biospecimens 
that will generate COVID-19 test results.   
15.4 Schedule and Content of Reports 
The following reports/dash boards will be developed: 
 
Report/ 
Dashboard Frequency  Purpose  Content  Reviewed by 
Unanticipated 
Problem 
(including 
Serious 
Adverse events 
and protocol 
deviations) 
Report Quarterly  To review unanticipated 
problems and provide an 
opportunity to refine protocol  Listing of unanticipated problem 
reports 
 Frequency of types of UP’s  PI 
 Chief of Clinical Protocol 
 Study Co‐Investigators 
 Research Assistant 
 
There will be no interim analysis performed.  Data analysis is detailed in Section 12.4.   
15.5 Study Records Retention 
Per Rutgers Research Regulatory Affairs, research that involves  collection of protected health information 
(PHI) is subject to the HIPAA regul ations. Research records inc luding signed consent forms that contain 
the HIPAA authorization must be re tained for 6 years after the date on which the subject signed the 
consent form or the date when it l ast was in effe ct, whichever is later. 
15.6 Protocol Deviations 
A protocol deviation is any cha nge, divergence, or departure fr om the study design or procedures of a 
research protocol that is under  the investigator's control and that has not been approved by the sIRB.  
Since the purpose of this feasib ility study is for protocol ref inement, any of the following will not be 
considered protocol violations unless the subject was put at ad ditional risk as a result of the divergence 
from the protocol. 
 Incomplete visits 
 Activities occurring outside  of the specified windows 
 Missing surveys/forms or data 
Upon discovery of a protocol dev iation, the Principal Investiga tor is responsible for  reporting protocol 
deviations to the sIRB. 
 A protocol violation is a devia tion from the sIRB approved prot ocol that may affect the subject's rights, 
safety, or well-being and/or the completeness, accuracy and rel iability of the study data. Protocol 
Violations must be submitted fo r Full Board sIRB review. If the  deviation meets any of the following 
criteria, it is considered a protocol violation. 
 All deviations and violations fr om the protocol will be recorde d on the Protocol Deviation/Violation 
Reporting Form no later than 10 business days after study staff  become aware o f the deviation and 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 53  forwarded to the study PI for re view and reported promptly to t he sIRB.   All protoc ol deviations and 
violations will be reviewed monthl y during the PREDICT Steering  Committee Meeting. 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 54  16 PUBLICATION/DATA SHARING  
This study will comply with a ll applicable NIH Data Sharing Pol icies. See 
https://grants.nih.gov/policy/sharing.htm  for policies and resources. 
 
Dissemination at Scientific Meetings:   Presentations at scientific meet ings will be delivered to assis t in 
dissemination of results as soon  as possible when final results  pertaining to the primary variables are 
available.  Meetings at which p resentations will be made includ e, but will not be limited to, American 
and International Association of D ental Research (AADR and IADR ), the American Dental Association 
(ADA), and International Associ ation for the Study of Pain (IAS P) and addiction meetings. NIH grant 
support will be acknowledged during all presentations. 
 
Publication and Authorship Policies: 
Findings will be published in peer -reviewed journals. Journals selected will be indexed in PubMed.  
Accepted manuscripts w ill be submitted to PubMed Central as per  NIH policy.  Example s of journals in 
which final results may be publ ished include the Journal of Den tal Research and the Journal of the 
American Dental Association.   Ot her medical journals, includin g journals on pain and addiction will be 
considered for manuscript public ations.  Final versions of the peer reviewed manuscripts will be made 
available to the public, generally  within 3 months but no later  than 12 months after the official date of 
publication.  NIH grant support w ill be acknowledged in all pub lications. 
 
Proposals from study investigator s for writing and submitting a bstracts and manuscript s for publication will 
be presented to a committee for approval, comprised of the stud y PI, chief clinical officer, chief 
pharmacology officer and chief sta tistician.  Included in the p roposal is data needed for the publication, 
analyses to be performed, propos ed authorship and order of auth orship, and/or journal in which the 
manuscript will be published.  If  a submission for an approved proposal is not completed within 11 months 
of approval, other authors can su bmit a similar proposal to the  committee for approval. 
 
The following ICMJE guidelines will be adopted and followed in determining authorship: 
 Substantial contributions to t he conception or design of the w ork; or the acquisition, analysis, or 
interpretation of data for the work; AND 
 Drafting the work or revising it critically for important inte llectual content; AND 
 Final approval of the version to be published; AND 
 Agreement to be accountable for all aspects of the work in ens uring that questions related to the 
accuracy or integrity of any part of the work are appropriately  investigated and resolved. 
 
The National Dental PBRN Publications and Presentations Policy is publicly available at 
http://www.nationaldentalpbrn.org/publications/ . 
 
NIH Public Access Policy 
The NIH Public Access Policy  requires scientists to submit fi nal peer-reviewed journal manu scripts that 
arise from NIH funds to PubMed Central  immediately upon acceptance for publication. This ensures that  
the public has access to the published results of NIH funded re search.  
 
The PI will share the individual n on-identified subject data no  later than acceptance for the publication’s 
main findings from the final data analysis or 18 months after c ompletion of the st udy, whichever is 
earlier.   As NIDCR does not have a data repository at the init iation of this feasibility study, data will be 
provided to the PBRN resource cen ter who will hav e the responsi bility for posting the data.  All study 
data will be collected in REDCAP wi th the REDCap project along with all non-identified data collected.  
The PBRN resource center will convert the data into both SAS an d ASCII formats for posting.  Data to 
be posted will include the study  protocol and the data set in b oth SAS and ASCII formats, and data 
dictionary.    
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 55  Upon written request to the PI, sur vey instruments or other mat erials developed for use during the 
clinical trial will be made electr onically available to other r esearchers.    
 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 56  17 LITERATURE REFERENCES 
 
1. American Dental Association . ADA Coronavirus (COVID-19) Cent er for Dentists. Available online: 
https://success.ada.or g/en/practice-managemen t/patients/infecti ous-diseases-2019-novel-
coronavirus? (accessed on 27 April 2020). 
2. COVID-19 resources from the ADA, visit the ADA Coronavirus ( COVID-19) Center for Dentists at 
ADA.org/virus. 
3. CDC guidelines: https://www.cdc .gov/oralhealth/infectioncon trol/statement-COVID.html  
4. ADA.org May 27, 2020 
5. Ge Z. et. al., Possible aeroso l transmission of COVID-19 and  special precautions in dentistry, J 
Zhejiang Univ-Sci B (Biomed & Biotechnol) https://doi.org/10.1631/jzus.B2010010 . 
6. Odeh, N.D. et. al., COVID-19: P resent and Future Challenges for Dental Practice. Int. J. Environ. 
Res. Public Health 2020, 17, 3151; doi:10.3390/ijerph17093151. 
7. Day, M. Covid-19: Four ﬁfths o f cases are asymp tomatic, Chin a ﬁgures indicate. BMJ 2020, 369, 
m1375. 
8. Kai-Wang To, K. et. al., Tempor al profiles of viral load in posterior oropharyngeal saliva samples 
and serum antibody responses during infection by SARS-CoV-2: an  observational cohort study. 
Lancet 2020, 20, 565-574. 
9. Rothe, C., et. al., Transmissi on of 2019-nCoV infection from  an asymptomatic contact in 
Germany. N. Engl. J. Med. 2020, 382, 970–971.. 
10. Helmy,Y.A. et al., The COVID- 19 Pandemic: A Comprehensive R eview of Taxonomy, Genetics, 
Epidemiology, Diagnosis, Treat ment, and Control. J. Clin. Med. 2020, 9, 1225; 
doi:10.3390/jcm9041225. 
11. Giacomelli, A.; et al. Self-r eported olfactory and taste di sorders in in patient s with severe acute 
respiratory coronavirus 2 infec tion: A cross-sectional study. C lin. Infect. Dis. 2 020. [CrossRef]. 
12. Schmalz et. a., Oral-Health-R elated Quality of Life in Adul t Patients with Rheumatic Diseases – A 
Systematic Review J. Clin. M ed. 2020, 9, 1172; doi:10.3390/jcm9 041172. 
13. Biju, R.M. ET AL., Oral Health  and Quality of Life: Current  Concepts. J Clin Diagnos Res, 2017, 
11, 21-26. 
14. Soldani FA,et. L.. One-to-one oral hygiene advice provided in a dental setting for oral health. 
Cochrane Database of S ystematic Reviews 2 018, Issue 10. Art. No .: CD007447. DOI: 
10.1002/14651858.CD007447.pub2. 
15. Lamont T, Routine scale and polish for periodontal health i n adults. 
Cochrane Database of S ystematic Reviews 2 018, Issue 12. Art. No .: CD004625. DOI: 
10.1002/14651858.CD004625.pub5. 
16. Shang, F.M., Liu H.L. Fusobacte rium nucelatum and colorecta l cancer: A mechanistic overview. 
World J Gastrointest Oncol. 2018 Mar 15;10(3):71-81. doi: 10.42 51/wjgo.v10.i3.71. 
17. Homlund A,et al., Oral health and cardiovascular disease ri sk in a cohort of periodontitis patients. 
Atherosclerosis. 2017 Jul;262:101 -106. doi: 10.1016/j.atheroscl erosis.2017.05.009. Epub 2017 
May 11. 
18. Berman CL. Screening by dentists for hypertension. N Engl J  Med, 1971, 286(26):1416. doi: 
10.1056/nejm197206292862616. 
19. Genco, R.J. et al. Screening for diabetes mellitus in denta l practices: a field trial.  J Am Dent 
Assoc. 2014 Jan;145(1):57- 64. doi: 10.14219/jada.2013.7. 
20. Huh, S. How to train health personnel to protect themselves  from SARA-CoV-2 (novel 
coronavirus) infection when cari ng for a patient or suspected c ase. J Educ Eval Health Prof 2020; 
17:10 • https://doi.org/10.3352/jeehp.2020.17.10  
21. WHO. Coronavirus Disease (CO VID-2019) Situation Reports-48.  Available online: 
https://www.who.in t/docs/ default-source/c oronaviruse/situation -reports/20200308-sitrep-48-
covid-19.pdf?sfvrsn=16f7ccef_4 (a ccessed on 10 March 2020). 
22. WHO. Clinical Management of Sev ere Acute Respiratory Infect ion When Novel Coronavirus 
(nCoV) Infection Is Suspected. Available online: https://www.wh o.int/publications-detail/clinical-
management-of-severeacute-respir atory-infection-when-novel-coro navirus-(ncov)-infection-is-
suspected (accessed on 17 March 2020). 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 57  23. Selvan, M.E. Risk factors fo r death from COVID-19. Nature R eviews Immunology | 
https://doi.org/10.1038/s41577-020 -0351-0 | Published online: 2 7 May 2020. 
24. Cantrill, JA et al., Indicato rs of the appropriateness of l ong term prescribing in general practice in 
the United Kingdom: con sensus developmen t, face and content val idity, feasibility, and reliability. 
Quality in Health Care 1998;7:130–135. 
25. Tibshirani, R. Regression Shrinkage and Selection via the l asso. J Royal Stat Soc Series B. Wiley 
1996,  58: 267-288. 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 58  SUPPLEMENTAL MATERIALS 
None 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 59  APPENDICES 
Table of Contents 
 
Appendix   Page  
  
Appendix A1:  Schedule of Events – Dental Health Care Workers S ubjects ?? 
  
Appendix B:  Schedule of Events – POC Patient Subjects ?? 
 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 60  APPENDIX A1: SCHEDULE OF EVENTS 
Dental Health Care Workers 
Procedures Prior to Enrollment  
Day -28 (+/- 29 days) Start-of-Study (Baseline) 
Day 0  Mid-Study 
Day 14 (+/- 7 days) End-of-Study 
Day 28 (+/- 7 days) 
Obtain Written Consent X    
Start-of-Study Survey  X   
Triage Survey  X X X 
End-of-Study Survey    X 
DHCW Participation Questionnaire    X 
POC Antigen Test  X X X 
PCR Viral Test  X  X 
ELISA Antibody Test  X  X 
 
 
Pragmatic Return to Effective D ental Infection Control Version PBRN Feasibility Study. Vr. 4.0 
Protocol X01 DE030407-01 8/15/21 
 
 
Based on NIDCR Interventional Protocol Template v5.0–20190311  Page 61  APPENDIX B: SCHEDULE OF EVENTS 
POC Patient Subject 
Procedures 2 Weeks Prior to 
Visit (Day -14 +/- 
14 days) Day Prior to Visit 
Day -2 (+/- 2 days) Visit 
Day 1  
Obtain Informed Consent X   
POC Antigen Test   X 
Triage Survey  X X 
Start-of-Visit Survey X   
End-of Visit Survey   X 
Patient Participation Questionnaire   X 
Provision of Dental Car e (Not part of study)   X 
 
 
 